BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//sec-api.dev//Biotech catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FDA calendar (sec-api.dev)
X-WR-CALDESC:PDUFA dates\, FDA advisory committees\, approvals and readouts
  for the next 30 days\, each with its source sentence. Independent. Not af
 filiated with\, endorsed by\, or sponsored by the U.S. Food and Drug Admin
 istration or the U.S. Securities and Exchange Commission. Dates are as sta
 ted by sponsors and FDA\; the FDA can act before or after a target date. N
 ot investment advice.
X-WR-TIMEZONE:America/New_York
X-PUBLISHED-TTL:PT6H
REFRESH-INTERVAL;VALUE=DURATION:PT6H
BEGIN:VEVENT
UID:09a875947bfeefb5@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:HARROW\, INC. earnings report (HROW)
DESCRIPTION:HARROW\, INC. earnings report (HROW): November 9\, 2026. Status
 : completed.\nPress release filed with the SEC (EX-99): "Harrow Announces 
 Third Quarter 2026 Financial Results" https://www.sec.gov/Archives/edgar/d
 ata/1360214/000162828026072195/hrow-20261109xpressrelease.htm\nDetails and
  all sources: https://sec-api.dev/companies/hrow/catalysts\nData as of 202
 6-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-ca
 lendar).
URL:https://sec-api.dev/companies/hrow/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:105842e2f5eab62b@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:AbCellera Biologics Inc. earnings report (ABCL)
DESCRIPTION:AbCellera Biologics Inc. earnings report (ABCL): November 9\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "VANCOU
 VER\, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today a
 nnounced financial results for the third quarter of 2026." https://www.sec
 .gov/Archives/edgar/data/1703057/000170305726000058/q32026earningspressrel
 ease.htm\nDetails and all sources: https://sec-api.dev/companies/abcl/cata
 lysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https
 ://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/abcl/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:12c530f51e170cf8@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Zymeworks Inc. earnings report (ZYME)
DESCRIPTION:Zymeworks Inc. earnings report (ZYME): November 9\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "Reports Third Qu
 arter 2026 Financial Results" https://www.sec.gov/Archives/edgar/data/1937
 653/000193765326000067/ex991q32026_earningsxrelea.htm\nDetails and all sou
 rces: https://sec-api.dev/companies/zyme/catalysts\nData as of 2026-11-16.
  sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/zyme/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:15fc2e6b4f4b6195@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Bicara Therapeutics Inc. earnings report (BCAX)
DESCRIPTION:Bicara Therapeutics Inc. earnings report (BCAX): November 9\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Bicara
  Therapeutics Reports Third Quarter 2026 Financial Results and Provides Bu
 siness Update" https://www.sec.gov/Archives/edgar/data/2023658/00016282802
 6071886/bicara-3q26earningspr.htm\nDetails and all sources: https://sec-ap
 i.dev/companies/bcax/catalysts\nData as of 2026-11-16. sec-api.dev biotech
  catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/bcax/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1a7bd842c498f71e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:HERON THERAPEUTICS\, INC. /DE/ earnings report (HRTX)
DESCRIPTION:HERON THERAPEUTICS\, INC. /DE/ earnings report (HRTX): November
  9\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "
 Heron Therapeutics Announces Third Quarter 2026 Financial Results" https:/
 /www.sec.gov/Archives/edgar/data/818033/000119312526452721/hrtx-ex99_1.htm
 \nDetails and all sources: https://sec-api.dev/companies/hrtx/catalysts\nD
 ata as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-a
 pi.dev/fda-calendar).
URL:https://sec-api.dev/companies/hrtx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2b1ea8a13e5b3ef3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Tonix Pharmaceuticals Holding Corp. earnings report (TNXP)
DESCRIPTION:Tonix Pharmaceuticals Holding Corp. earnings report (TNXP): Nov
 ember 9\, 2026. Status: completed.\nPress release filed with the SEC (EX-9
 9): "Pharmaceuticals Reports Third Quarter 2026 Financial Results and Oper
 ational Highlights" https://www.sec.gov/Archives/edgar/data/1430306/000149
 315226050621/ex99-01.htm\nDetails and all sources: https://sec-api.dev/com
 panies/tnxp/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst
  calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tnxp/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2c68775919c109cb@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:ZEVASKYN (zevaskyn) earnings report (ABEO)
DESCRIPTION:ZEVASKYN (zevaskyn) earnings report (ABEO): November 9\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "Therapeutic
 s® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial
  Progress" https://www.sec.gov/Archives/edgar/data/318306/0001493152260506
 09/ex99-1.htm\nDetails and all sources: https://sec-api.dev/pdufa/zevaskyn
 \nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://se
 c-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/zevaskyn
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:31e34609f20f09dd@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261105T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:JANX011 interim data readout (JANX)
DESCRIPTION:JANX011 interim data readout (JANX): November 9\, 2026. Status:
  scheduled.\nPress release filed with the SEC (EX-99): "Initial clinical d
 ata from the study will be presented during an investor webcast on Novembe
 r 9\, 2026." https://www.sec.gov/Archives/edgar/data/1817713/0001193125264
 49790/janx-ex99_1.htm\nDetails and all sources: https://sec-api.dev/pdufa/
 janx011\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (htt
 ps://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/janx011
CATEGORIES:interim data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:34be822534d3bca2@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:TG THERAPEUTICS\, INC. earnings report (TGTX)
DESCRIPTION:TG THERAPEUTICS\, INC. earnings report (TGTX): November 9\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "TG Thera
 peutics Reports Third Quarter 2026 Financial Results and Raises Full-Year 
 Revenue Guidance" https://www.sec.gov/Archives/edgar/data/1001316/00016282
 8026071870/q3-26earningsprxexx991.htm\nDetails and all sources: https://se
 c-api.dev/companies/tgtx/catalysts\nData as of 2026-11-16. sec-api.dev bio
 tech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tgtx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:35c412754828c555@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:CervoMed Inc. earnings report (CRVO)
DESCRIPTION:CervoMed Inc. earnings report (CRVO): November 9\, 2026. Status
 : completed.\nPress release filed with the SEC (EX-99): "CervoMed Reports 
 Third Quarter 2026 Financial Results and Provides Corporate Updates" https
 ://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.h
 tm\nDetails and all sources: https://sec-api.dev/companies/crvo/catalysts\
 nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec
 -api.dev/fda-calendar).
URL:https://sec-api.dev/companies/crvo/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:37138aaa8b644295@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Atea Pharmaceuticals\, Inc. earnings report (AVIR)
DESCRIPTION:Atea Pharmaceuticals\, Inc. earnings report (AVIR): November 9\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Ate
 a Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provide
 s Business Update" https://www.sec.gov/Archives/edgar/data/1593899/0001193
 12526453636/d177149dex991.htm\nDetails and all sources: https://sec-api.de
 v/companies/avir/catalysts\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/avir/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3962d2250f4084d2@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Zentalis Pharmaceuticals\, Inc. earnings report (ZNTL)
DESCRIPTION:Zentalis Pharmaceuticals\, Inc. earnings report (ZNTL): Novembe
 r 9\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): 
 "Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and
  Business Updates" https://www.sec.gov/Archives/edgar/data/1725160/0001725
 16026000069/zntlq32026pressrelease.htm\nDetails and all sources: https://s
 ec-api.dev/companies/zntl/catalysts\nData as of 2026-11-16. sec-api.dev bi
 otech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/zntl/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3b113ac69908e7c1@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:ImmunityBio\, Inc. earnings report (IBRX)
DESCRIPTION:ImmunityBio\, Inc. earnings report (IBRX): November 9\, 2026. S
 tatus: completed.\nPress release filed with the SEC (EX-99): "November 9\,
  2026 — ImmunityBio\, Inc. (NASDAQ: IBRX)\, a commercial-stage immunothe
 rapy company\, today announced continued global expansion\, expanded FDA a
 pproval\, and financial results for the third quarter ended September 30\,
  2026." https://www.sec.gov/Archives/edgar/data/1326110/000132611026000097
 /ibrx-2026119x8kexhibit991.htm\nDetails and all sources: https://sec-api.d
 ev/companies/ibrx/catalysts\nData as of 2026-11-16. sec-api.dev biotech ca
 talyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ibrx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3b258e232371d1f6@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Attovia Therapeutics\, Inc. earnings report (ATTO)
DESCRIPTION:Attovia Therapeutics\, Inc. earnings report (ATTO): November 9\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Att
 ovia Therapeutics Reports Third Quarter 2026 Financial Results and Provide
 s a Corporate Update" https://www.sec.gov/Archives/edgar/data/2058707/0001
 19312526453592/atto-ex99_1.htm\nDetails and all sources: https://sec-api.d
 ev/companies/atto/catalysts\nData as of 2026-11-16. sec-api.dev biotech ca
 talyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/atto/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:445ebcf97d763cfc@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Neurogene earnings report (NGNE)
DESCRIPTION:Neurogene earnings report (NGNE): November 9\, 2026. Status: co
 mpleted.\nPress release filed with the SEC (EX-99): "Neurogene Reports Thi
 rd Quarter 2026 Financial Results and Highlights Recent Updates" https://w
 ww.sec.gov/Archives/edgar/data/1404644/000140464426000064/ngne_3qye26earni
 ngsrelease.htm\nDetails and all sources: https://sec-api.dev/pdufa/neuroge
 ne\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://
 sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/neurogene
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:460560d2e752c69c@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:AN2 Therapeutics\, Inc. earnings report (ANTX)
DESCRIPTION:AN2 Therapeutics\, Inc. earnings report (ANTX): November 9\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "AN2 The
 rapeutics Reports Third Quarter 2026 Financial Results and Recent Business
  and Scientific Highlights" https://www.sec.gov/Archives/edgar/data/188043
 8/000119312526452660/antx-ex99_1.htm\nDetails and all sources: https://sec
 -api.dev/companies/antx/catalysts\nData as of 2026-11-16. sec-api.dev biot
 ech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/antx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:469a72f671efcf3c@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Immunome Inc. earnings report (IMNM)
DESCRIPTION:Immunome Inc. earnings report (IMNM): November 9\, 2026. Status
 : completed.\nPress release filed with the SEC (EX-99): "Immunome Reports 
 Third Quarter 2026 Financial Results and Provides Business Update" https:/
 /www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.ht
 m\nDetails and all sources: https://sec-api.dev/companies/imnm/catalysts\n
 Data as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-
 api.dev/fda-calendar).
URL:https://sec-api.dev/companies/imnm/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5095fa471bed760d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Structure Therapeutics Inc. earnings report (GPCR)
DESCRIPTION:Structure Therapeutics Inc. earnings report (GPCR): November 9\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "The
 rapeutics Inc. (NASDAQ: GPCR)\, a clinical-stage global biopharmaceutical 
 company developing novel oral small molecule therapeutics for metabolic di
 seases\, with a focus on obesity\, today reported financial results for th
 e third quarter ended September 30\, 2026\, and provided a business update
  across its oral small molecule obesity portfolio." https://www.sec.gov/Ar
 chives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm\nDetai
 ls and all sources: https://sec-api.dev/companies/gpcr/catalysts\nData as 
 of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/
 fda-calendar).
URL:https://sec-api.dev/companies/gpcr/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:50b51c39c04a90ed@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:IONIS PHARMACEUTICALS INC earnings report (IONS)
DESCRIPTION:IONIS PHARMACEUTICALS INC earnings report (IONS): November 9\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Ionis
  reports third quarter 2026 financial results and highlights progress on k
 ey programs" https://www.sec.gov/Archives/edgar/data/874015/00011403612604
 2598/ef20085128_ex99-1.htm\nDetails and all sources: https://sec-api.dev/c
 ompanies/ions/catalysts\nData as of 2026-11-16. sec-api.dev biotech cataly
 st calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ions/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5944aeee523225cf@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Turn Therapeutics Inc. earnings report (TTRX)
DESCRIPTION:Turn Therapeutics Inc. earnings report (TTRX): November 9\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "Turn The
 rapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financ
 ial Results" https://www.sec.gov/Archives/edgar/data/2023016/0001213900261
 17180/ea031139901ex99-1.htm\nDetails and all sources: https://sec-api.dev/
 companies/ttrx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ttrx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5f711b9801cab6cf@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Xenon Pharmaceuticals Inc. earnings report (XENE)
DESCRIPTION:Xenon Pharmaceuticals Inc. earnings report (XENE): November 9\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Xeno
 n Reports Q3 2026 Financial Results and Provides Business Update" https://
 www.sec.gov/Archives/edgar/data/1582313/000119312526453521/xene-ex99_1.htm
 \nDetails and all sources: https://sec-api.dev/companies/xene/catalysts\nD
 ata as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-a
 pi.dev/fda-calendar).
URL:https://sec-api.dev/companies/xene/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:626c2921c3028b01@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Veradermics\, Inc topline data readout (MANE)
DESCRIPTION:Veradermics\, Inc topline data readout (MANE): November 9\, 202
 6. Status: completed (positive).\nSEC Form 8-K: "On November 9\, 2026\, th
 e Company announced positive topline results from Part B of its randomized
 \, double-blind\, placebo-controlled\, registration-directed Phase 2/3 cli
 nical trial (Study '302') evaluating VDPHL01\, an investigational\, propri
 etary\, extended-release oral minoxidil formulation\, in over 500 males wi
 th mild-to-moderate pattern hair loss." https://www.sec.gov/Archives/edgar
 /data/1827635/000182763526000038/mane-20261109.htm\nDetails and all source
 s: https://sec-api.dev/companies/mane/catalysts\nData as of 2026-11-16. se
 c-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mane/catalysts
CATEGORIES:topline data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6622db5ec6dce9ed@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:SIGA TECHNOLOGIES INC earnings report (SIGA)
DESCRIPTION:SIGA TECHNOLOGIES INC earnings report (SIGA): November 9\, 2026
 . Status: completed.\nPress release filed with the SEC (EX-99): "SIGA Repo
 rts Financial Results for Three and Nine Months Ended September 30\, 2026"
  https://www.sec.gov/Archives/edgar/data/1010086/000114036126042783/ef2008
 5184_ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/si
 ga/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar
  (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/siga/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:68245b3cade9b336@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:SPRUCE BIOSCIENCES\, INC. earnings report (SPRB)
DESCRIPTION:SPRUCE BIOSCIENCES\, INC. earnings report (SPRB): November 9\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Spruc
 e Biosciences Reports Third Quarter 2026 Financial Results and Provides Co
 rporate Updates" https://www.sec.gov/Archives/edgar/data/1683553/000119312
 526452707/sprb-ex99_1.htm\nDetails and all sources: https://sec-api.dev/co
 mpanies/sprb/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/sprb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:69ab00025020f760@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Surrozen\, Inc./DE earnings report (SRZN)
DESCRIPTION:Surrozen\, Inc./DE earnings report (SRZN): November 9\, 2026. S
 tatus: completed.\nPress release filed with the SEC (EX-99): "Surrozen Rep
 orts Third Quarter 2026 Financial Results and Provides Business Update" ht
 tps://www.sec.gov/Archives/edgar/data/1824893/000119312526453641/srzn-ex99
 _1.htm\nDetails and all sources: https://sec-api.dev/companies/srzn/cataly
 sts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:/
 /sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/srzn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6de73b6d5f5617b7@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:MAXCYTE\, INC. earnings report (MXCT)
DESCRIPTION:MAXCYTE\, INC. earnings report (MXCT): November 9\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "MD\, November 10
 \, 2026 — MaxCyte\, Inc. (NASDAQ: MXCT)\, a leading cell-engineering com
 pany providing enabling platform technologies to advance the discovery\, d
 evelopment and commercialization of next-generation cell therapeutics\, to
 day announced its third quarter ended September 30\, 2026 financial result
 s and raised its 2026 total revenue guidance." https://www.sec.gov/Archive
 s/edgar/data/1287098/000110465926124829/tm2629420d1_ex99-1.htm\nDetails an
 d all sources: https://sec-api.dev/companies/mxct/catalysts\nData as of 20
 26-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-c
 alendar).
URL:https://sec-api.dev/companies/mxct/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7298de7a77442610@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:OCULAR THERAPEUTIX\, INC earnings report (OCUL)
DESCRIPTION:OCULAR THERAPEUTIX\, INC earnings report (OCUL): November 9\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Report
 s Third Quarter 2026 Financial Results and Business Highlights" https://ww
 w.sec.gov/Archives/edgar/data/1393434/000110465926124151/tm2629079d2_ex99-
 1.htm\nDetails and all sources: https://sec-api.dev/companies/ocul/catalys
 ts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://
 sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ocul/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7637e1d56a9f8221@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Mereo BioPharma Group plc earnings report (MREO)
DESCRIPTION:Mereo BioPharma Group plc earnings report (MREO): November 9\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Mereo
  BioPharma Reports Third Quarter 2026 Financial Results" https://www.sec.g
 ov/Archives/edgar/data/1719714/000119312526452716/mreo-ex99_1.htm\nDetails
  and all sources: https://sec-api.dev/companies/mreo/catalysts\nData as of
  2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fd
 a-calendar).
URL:https://sec-api.dev/companies/mreo/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7a69ead0909190a8@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Praxis Precision Medicines\, Inc. earnings report (PRAX)
DESCRIPTION:Praxis Precision Medicines\, Inc. earnings report (PRAX): Novem
 ber 9\, 2026. Status: completed.\nPress release filed with the SEC (EX-99)
 : "Praxis Precision Medicines Provides Corporate Update and Reports Third 
 Quarter 2026 Financial Results" https://www.sec.gov/Archives/edgar/data/16
 89548/000168954826000086/praxisq32026pr.htm\nDetails and all sources: http
 s://sec-api.dev/companies/prax/catalysts\nData as of 2026-11-16. sec-api.d
 ev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/prax/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7a9704ed07170f00@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Trevi Therapeutics\, Inc. earnings report (TRVI)
DESCRIPTION:Trevi Therapeutics\, Inc. earnings report (TRVI): November 9\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Trevi
  Therapeutics Reports Third Quarter 2026 Financial Results and Provides Bu
 siness Updates" https://www.sec.gov/Archives/edgar/data/1563880/0001193125
 26453670/trvi-ex99_1.htm\nDetails and all sources: https://sec-api.dev/com
 panies/trvi/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst
  calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/trvi/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7cdc5dd45d343e7f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Whitehawk Therapeutics\, Inc. earnings report (WHWK)
DESCRIPTION:Whitehawk Therapeutics\, Inc. earnings report (WHWK): November 
 9\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "W
 hitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Rec
 ent Highlights" https://www.sec.gov/Archives/edgar/data/1422142/0001193125
 26452704/whwk-ex99_1.htm\nDetails and all sources: https://sec-api.dev/com
 panies/whwk/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst
  calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/whwk/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:87cecc145fa90696@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Lifevantage Corp earnings report (LFVN)
DESCRIPTION:Lifevantage Corp earnings report (LFVN): November 9\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "LifeVantage An
 nounces Financial Results for the First Quarter Fiscal 2027" https://www.s
 ec.gov/Archives/edgar/data/849146/000119312526453570/lfvn-ex99_1.htm\nDeta
 ils and all sources: https://sec-api.dev/companies/lfvn/catalysts\nData as
  of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev
 /fda-calendar).
URL:https://sec-api.dev/companies/lfvn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:89094a4aa7a911cb@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Perspective Therapeutics\, Inc. earnings report (CATX)
DESCRIPTION:Perspective Therapeutics\, Inc. earnings report (CATX): Novembe
 r 9\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): 
 "SEATTLE - November 9\, 2026 - Perspective Therapeutics\, Inc. ("Perspecti
 ve\," the "Company\," "we\," "us\," and "our") (NYSE AMERICAN: CATX)\, a r
 adiopharmaceutical development company pioneering advanced systemic treatm
 ents for cancers\, today provided a business update and announced results 
 for the quarter ended September 30\, 2026." https://www.sec.gov/Archives/e
 dgar/data/728387/000119312526453708/catx-ex99_1.htm\nDetails and all sourc
 es: https://sec-api.dev/companies/catx/catalysts\nData as of 2026-11-16. s
 ec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/catx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8c6ddbf329826763@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Coherus Oncology\, Inc. earnings report (CHRS)
DESCRIPTION:Coherus Oncology\, Inc. earnings report (CHRS): November 9\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Coherus
  Oncology Reports Third Quarter 2026 Financial Results and Announces Strat
 egic Prioritization Plan" https://www.sec.gov/Archives/edgar/data/1512762/
 000110465926124511/chrs-ex99d1.htm\nDetails and all sources: https://sec-a
 pi.dev/companies/chrs/catalysts\nData as of 2026-11-16. sec-api.dev biotec
 h catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/chrs/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8dd1ae72f6ed70f6@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:MBX Biosciences\, Inc. earnings report (MBX)
DESCRIPTION:MBX Biosciences\, Inc. earnings report (MBX): November 9\, 2026
 . Status: completed.\nPress release filed with the SEC (EX-99): "MBX Biosc
 iences Reports Third Quarter 2026 Financial Results and Corporate Highligh
 ts" https://www.sec.gov/Archives/edgar/data/1776111/000119312526453553/mbx
 -ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/mbx/ca
 talysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (htt
 ps://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mbx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:927e47b0d976f6da@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Editas Medicine\, Inc. earnings report (EDIT)
DESCRIPTION:Editas Medicine\, Inc. earnings report (EDIT): November 9\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "Editas M
 edicine Announces Third Quarter 2026 Results and Business Updates" https:/
 /www.sec.gov/Archives/edgar/data/1650664/000165066426000100/editasmedicine
 pressrelease.htm\nDetails and all sources: https://sec-api.dev/companies/e
 dit/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calenda
 r (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/edit/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9abb135e41b6e451@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:ADC Therapeutics SA earnings report (ADCT)
DESCRIPTION:ADC Therapeutics SA earnings report (ADCT): November 9\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "ADC Therape
 utics Reports Third Quarter 2026 Financial Results and Provides Operationa
 l Updates" https://www.sec.gov/Archives/edgar/data/1771910/000162828026071
 899/adct-20260930pressrelease.htm\nDetails and all sources: https://sec-ap
 i.dev/companies/adct/catalysts\nData as of 2026-11-16. sec-api.dev biotech
  catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/adct/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9c3ca037fb00b81f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Compass Therapeutics\, Inc. earnings report (CMPX)
DESCRIPTION:Compass Therapeutics\, Inc. earnings report (CMPX): November 9\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Com
 pass Therapeutics Reports 2026 Third Quarter Financial Results and Provide
 s Corporate Update" https://www.sec.gov/Archives/edgar/data/1738021/000117
 184326007256/exh_991.htm\nDetails and all sources: https://sec-api.dev/com
 panies/cmpx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst
  calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cmpx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b36c4389bb1c461d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Aura Biosciences\, Inc. earnings report (AURA)
DESCRIPTION:Aura Biosciences\, Inc. earnings report (AURA): November 9\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Aura Bi
 osciences Reports Third Quarter 2026 Financial Results and Recent Business
  Highlights" https://www.sec.gov/Archives/edgar/data/1501796/0001193125264
 52620/aura-ex99_1.htm\nDetails and all sources: https://sec-api.dev/compan
 ies/aura/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst ca
 lendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/aura/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b935ba0ab42f8cbd@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Maze Therapeutics\, Inc. earnings report (MAZE)
DESCRIPTION:Maze Therapeutics\, Inc. earnings report (MAZE): November 9\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Maze T
 herapeutics Reports Third Quarter 2026 Financial Results and Recent Highli
 ghts" https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/m
 aze-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/maz
 e/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar 
 (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/maze/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d3616c32a145c834@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Roivant Sciences Ltd. earnings report (ROIV)
DESCRIPTION:Roivant Sciences Ltd. earnings report (ROIV): November 9\, 2026
 . Status: completed.\nPress release filed with the SEC (EX-99): "Roivant R
 eports Financial Results for the Second Quarter Ended September 30\, 2026\
 , and Provides Business Update" https://www.sec.gov/Archives/edgar/data/16
 35088/000163508826000130/q2fy2026roivantearningsrel.htm\nDetails and all s
 ources: https://sec-api.dev/companies/roiv/catalysts\nData as of 2026-11-1
 6. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar
 ).
URL:https://sec-api.dev/companies/roiv/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dd2a377b5b0033ab@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Tango Therapeutics\, Inc. earnings report (TNGX)
DESCRIPTION:Tango Therapeutics\, Inc. earnings report (TNGX): November 9\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Tango
  Therapeutics Reports Third Quarter 2026 Financial Results and Provides Bu
 siness Highlights" https://www.sec.gov/Archives/edgar/data/1819133/0001193
 12526452635/tngx-ex99_1.htm\nDetails and all sources: https://sec-api.dev/
 companies/tngx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tngx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e27def8426961aeb@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:KALA BIO\, Inc. earnings report (KALA)
DESCRIPTION:KALA BIO\, Inc. earnings report (KALA): November 9\, 2026. Stat
 us: completed.\nPress release filed with the SEC (EX-99): "York\, November
  9\, 2026 - KALA BIO\, Inc. (Nasdaq: KALA) today announced preliminary una
 udited financial results for the quarter ended September 30\, 2026." https
 ://www.sec.gov/Archives/edgar/data/1479419/000182912626012118/kalabio_ex99
 -1.htm\nDetails and all sources: https://sec-api.dev/companies/kala/cataly
 sts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:/
 /sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/kala/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:eb0b38ddc5e5c6e9@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Septerna\, Inc. earnings report (SEPN)
DESCRIPTION:Septerna\, Inc. earnings report (SEPN): November 9\, 2026. Stat
 us: completed.\nPress release filed with the SEC (EX-99): "Septerna Highli
 ghts Business Progress and Reports Third Quarter 2026 Financial Results" h
 ttps://www.sec.gov/Archives/edgar/data/1984086/000119312526453547/sepn-ex9
 9_1.htm\nDetails and all sources: https://sec-api.dev/companies/sepn/catal
 ysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:
 //sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/sepn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f20daa4977108ba7@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:ImageneBio\, Inc. earnings report (IMA)
DESCRIPTION:ImageneBio\, Inc. earnings report (IMA): November 9\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "ImageneBio Rep
 orts Third Quarter 2026 Financial Results" https://www.sec.gov/Archives/ed
 gar/data/1835579/000119312526453639/d139863dex991.htm\nDetails and all sou
 rces: https://sec-api.dev/companies/ima/catalysts\nData as of 2026-11-16. 
 sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ima/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f3492f0e620db118@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Annexon\, Inc. earnings report (ANNX)
DESCRIPTION:Annexon\, Inc. earnings report (ANNX): November 9\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "Annexon Reports 
 Third Quarter 2026 Financial Results\, Business Updates and Key Anticipate
 d Milestones" https://www.sec.gov/Archives/edgar/data/1528115/000119312526
 453557/annx-ex99_1.htm\nDetails and all sources: https://sec-api.dev/compa
 nies/annx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst c
 alendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/annx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f4460a2bf0e8e6fd@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Rani Therapeutics Holdings\, Inc. earnings report (RANI)
DESCRIPTION:Rani Therapeutics Holdings\, Inc. earnings report (RANI): Novem
 ber 9\, 2026. Status: completed.\nPress release filed with the SEC (EX-99)
 : "Rani Therapeutics Reports Third Quarter 2026 Financial Results\; Provid
 es Corporate Update" https://www.sec.gov/Archives/edgar/data/1856725/00011
 9312526453804/rani-ex99_1.htm\nDetails and all sources: https://sec-api.de
 v/companies/rani/catalysts\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/rani/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fd17c5a91f454897@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:NKX019 interim data readout (NKTX)
DESCRIPTION:NKX019 interim data readout (NKTX): November 9\, 2026. Status: 
 completed (positive).\nPress release filed with the SEC (EX-99): "SOUTH SA
 N FRANCISCO\, Calif.\, November 9\, 2026 — Nkarta (Nasdaq: NKTX)\, a cli
 nical-stage biotechnology company developing engineered natural killer (NK
 ) cell therapies to treat autoimmune diseases\, today announced positive i
 nitial clinical data from its Ntrust clinical trial program evaluating NKX
 019\, its allogeneic\, off-the-shelf CAR NK cell therapy candidate." https
 ://www.sec.gov/Archives/edgar/data/1787400/000178740026000027/nktx-ex99_1.
 htm\nDetails and all sources: https://sec-api.dev/pdufa/nkx019\nData as of
  2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fd
 a-calendar).
URL:https://sec-api.dev/pdufa/nkx019
CATEGORIES:interim data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fdbc405dcb3e1af2@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Immunovant\, Inc. earnings report (IMVT)
DESCRIPTION:Immunovant\, Inc. earnings report (IMVT): November 9\, 2026. St
 atus: completed.\nPress release filed with the SEC (EX-99): "Immunovant Pr
 ovides Corporate Updates and Reports Financial Results for the Quarter End
 ed September 30\, 2026" https://www.sec.gov/Archives/edgar/data/1764013/00
 0176401326000121/exhibit9912026119.htm\nDetails and all sources: https://s
 ec-api.dev/companies/imvt/catalysts\nData as of 2026-11-16. sec-api.dev bi
 otech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/imvt/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:nct05936151-readout@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261116T102001Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:Retatrutide topline data readout (LLY)
DESCRIPTION:Retatrutide topline data readout (LLY): November 9\, 2026. Stat
 us: completed.\nClinicalTrials.gov: "NCT05936151 (A Study of Retatrutide (
 LY3437943) on Renal Function in Participants With Overweight or Obesity an
 d Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status 
 COMPLETED\; Phase PHASE2\; Primary Completion 2025-10-01 (ACTUAL)\; Lead S
 ponsor Eli Lilly and Company\; Results First Posted 2026-11-09." https://c
 linicaltrials.gov/study/NCT05936151?tab=results\nDetails and all sources: 
 https://sec-api.dev/pdufa/retatrutide\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/retatrutide
CATEGORIES:topline data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:10127672c40df1fc@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Coya Therapeutics\, Inc. earnings report (COYA)
DESCRIPTION:Coya Therapeutics\, Inc. earnings report (COYA): November 10\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Coya 
 Therapeutics Reports Third Quarter 2026 Financial Results and Provides a C
 orporate Update" https://www.sec.gov/Archives/edgar/data/1835022/000119312
 526454473/coya-ex99_1.htm\nDetails and all sources: https://sec-api.dev/co
 mpanies/coya/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/coya/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:10e1c645c4c141f1@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Ovid Therapeutics Inc. earnings report (OVID)
DESCRIPTION:Ovid Therapeutics Inc. earnings report (OVID): November 10\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Ovid Th
 erapeutics Reports Business Updates and Third Quarter 2026 Financial Resul
 ts" https://www.sec.gov/Archives/edgar/data/1636651/000162828026072494/ovi
 dexhibit9912026-q3.htm\nDetails and all sources: https://sec-api.dev/compa
 nies/ovid/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst c
 alendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ovid/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1160fd8c6f626bde@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Kalaris Therapeutics\, Inc. earnings report (KLRS)
DESCRIPTION:Kalaris Therapeutics\, Inc. earnings report (KLRS): November 10
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Ka
 laris Reports Third Quarter 2026 Financial Results and Provides Business U
 pdate" https://www.sec.gov/Archives/edgar/data/1754068/000119312526454454/
 d164715dex991.htm\nDetails and all sources: https://sec-api.dev/companies/
 klrs/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calend
 ar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/klrs/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:14caaaa6748dd5be@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:CITY THERAPEUTICS\, INC. trial start (CTY)
DESCRIPTION:CITY THERAPEUTICS\, INC. trial start (CTY): November 10\, 2026.
  Status: completed.\nPress release filed with the SEC (EX-99): "Mass.\, No
 vember 10\, 2026 - City Therapeutics\, Inc. (Nasdaq: CTY)\, a clinical-sta
 ge biotechnology company engineering the next generation of RNA interferen
 ce (RNAi) therapeutics\, today announced that the first participant has be
 en dosed in the Phase 1 clinical trial of CITY-RBP4\, an investigational R
 NAi therapeutic candidate for the treatment of Stargardt disease type 1 (S
 targardt disease)." https://www.sec.gov/Archives/edgar/data/2143850/000110
 465926124775/tm2629408d1_ex99-1.htm\nDetails and all sources: https://sec-
 api.dev/companies/cty/catalysts\nData as of 2026-11-16. sec-api.dev biotec
 h catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cty/catalysts
CATEGORIES:trial start
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:16827cc9631d6c3b@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:AUCATZYL (obecabtagene autoleucel) earnings report (AUTL)
DESCRIPTION:AUCATZYL (obecabtagene autoleucel) earnings report (AUTL): Nove
 mber 10\, 2026. Status: completed.\nPress release filed with the SEC (EX-9
 9): "Autolus Therapeutics Reports Third Quarter 2026 Financial Results and
  Business Updates November 10\, 2026 at 7:00 AM EST Company reports AUCATZ
 YL® (obecabtagene autoleucel" https://www.sec.gov/Archives/edgar/data/173
 0463/000173046326000141/autlex-991pr111026.htm\nDetails and all sources: h
 ttps://sec-api.dev/pdufa/obecabtagene-autoleucel\nData as of 2026-11-16. s
 ec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/obecabtagene-autoleucel
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2258c793ef5941e9@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:CAPRICOR THERAPEUTICS\, INC. earnings report (CAPR)
DESCRIPTION:CAPRICOR THERAPEUTICS\, INC. earnings report (CAPR): November 1
 0\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "C
 apricor Therapeutics Reports Third Quarter 2026 Financial Results and Prov
 ides Corporate Update" https://www.sec.gov/Archives/edgar/data/1133869/000
 110465926125150/capr-ex99d1.htm\nDetails and all sources: https://sec-api.
 dev/companies/capr/catalysts\nData as of 2026-11-16. sec-api.dev biotech c
 atalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/capr/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2b518aacdd9ab08f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:NextCure\, Inc. earnings report (NXTC)
DESCRIPTION:NextCure\, Inc. earnings report (NXTC): November 10\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "Reports Third 
 Quarter 2026 Financial Results" https://www.sec.gov/Archives/edgar/data/16
 61059/000110465926125188/nxtc-ex99d1.htm\nDetails and all sources: https:/
 /sec-api.dev/companies/nxtc/catalysts\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/nxtc/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:31934c4865514728@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Xilio Therapeutics\, Inc. earnings report (XLO)
DESCRIPTION:Xilio Therapeutics\, Inc. earnings report (XLO): November 10\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Xilio
  Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pi
 peline and Business Updates" https://www.sec.gov/Archives/edgar/data/18402
 33/000119312526454449/xlo-ex99_1.htm\nDetails and all sources: https://sec
 -api.dev/companies/xlo/catalysts\nData as of 2026-11-16. sec-api.dev biote
 ch catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/xlo/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:392e2c1e8ebd42ad@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:PALI-2108 earnings report (PALI)
DESCRIPTION:PALI-2108 earnings report (PALI): November 10\, 2026. Status: c
 ompleted.\nPress release filed with the SEC (EX-99): "Palisade Bio Reports
  Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clini
 cal Development Programs" https://www.sec.gov/Archives/edgar/data/1357459/
 000135745926000025/pali-ex99_1.htm\nDetails and all sources: https://sec-a
 pi.dev/pdufa/pali-2108\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/pali-2108
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4543a8d994a33488@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Cardiff Oncology\, Inc. earnings report (CRDF)
DESCRIPTION:Cardiff Oncology\, Inc. earnings report (CRDF): November 10\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Cardif
 f Oncology Reports Third Quarter 2026 Results and Provides Business Update
 " https://www.sec.gov/Archives/edgar/data/1213037/000119312526458500/crdf-
 ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/crdf/ca
 talysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (htt
 ps://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/crdf/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:45d5275592bec95b@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Alto Neuroscience\, Inc. earnings report (ANRO)
DESCRIPTION:Alto Neuroscience\, Inc. earnings report (ANRO): November 10\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Alto 
 Neuroscience Reports Third Quarter 2026 Financial Results and Recent Busin
 ess Highlights" https://www.sec.gov/Archives/edgar/data/1999480/0001999480
 26000030/exhibit991-earningsrelease.htm\nDetails and all sources: https://
 sec-api.dev/companies/anro/catalysts\nData as of 2026-11-16. sec-api.dev b
 iotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/anro/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:521d398dc735042b@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Corbus Pharmaceuticals Holdings\, Inc. earnings report (CRBP)
DESCRIPTION:Corbus Pharmaceuticals Holdings\, Inc. earnings report (CRBP): 
 November 10\, 2026. Status: completed.\nPress release filed with the SEC (
 EX-99): "Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Prov
 ides a Corporate Update o" https://www.sec.gov/Archives/edgar/data/1595097
 /000119312526454476/crbp-ex99_1.htm\nDetails and all sources: https://sec-
 api.dev/companies/crbp/catalysts\nData as of 2026-11-16. sec-api.dev biote
 ch catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/crbp/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5292272fc42a0ba3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:CalciMedica\, Inc. earnings report (CALC)
DESCRIPTION:CalciMedica\, Inc. earnings report (CALC): November 10\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "CalciMedica
  Reports Third Quarter 2026 Financial Results and Provides Clinical & Corp
 orate Updates" https://www.sec.gov/Archives/edgar/data/1534133/00011931252
 6454430/ck0001534133-ex99_1.htm\nDetails and all sources: https://sec-api.
 dev/companies/calc/catalysts\nData as of 2026-11-16. sec-api.dev biotech c
 atalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/calc/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5327220cd2755d84@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Scholar Rock Holding Corp earnings report (SRRK)
DESCRIPTION:Scholar Rock Holding Corp earnings report (SRRK): November 10\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Scho
 lar Rock Reports Third Quarter 2026 Financial Results and Recent Business 
 Highlights" https://www.sec.gov/Archives/edgar/data/1727196/00011931252645
 4423/srrk-ex99_1.htm\nDetails and all sources: https://sec-api.dev/compani
 es/srrk/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst cal
 endar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/srrk/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:588138339142833e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Dermata Therapeutics\, Inc. earnings report (DRMA)
DESCRIPTION:Dermata Therapeutics\, Inc. earnings report (DRMA): November 10
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Re
 ports Financial Results for the Third Quarter 2026" https://www.sec.gov/Ar
 chives/edgar/data/1853816/000149315226050964/ex99-1.htm\nDetails and all s
 ources: https://sec-api.dev/companies/drma/catalysts\nData as of 2026-11-1
 6. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar
 ).
URL:https://sec-api.dev/companies/drma/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5bc6bea9729220a2@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Cullinan Therapeutics\, Inc. earnings report (CGEM)
DESCRIPTION:Cullinan Therapeutics\, Inc. earnings report (CGEM): November 1
 0\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "C
 ullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2
 026 Financial Results" https://www.sec.gov/Archives/edgar/data/1789972/000
 119312526454408/cgem-ex99_1.htm\nDetails and all sources: https://sec-api.
 dev/companies/cgem/catalysts\nData as of 2026-11-16. sec-api.dev biotech c
 atalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cgem/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5bfb0cb6898294cc@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Hemab Therapeutics Holdings\, Inc. earnings report (COAG)
DESCRIPTION:Hemab Therapeutics Holdings\, Inc. earnings report (COAG): Nove
 mber 10\, 2026. Status: completed.\nPress release filed with the SEC (EX-9
 9): "Hemab Therapeutics Reports Third Quarter 2026 Financial Results and P
 rovides" https://www.sec.gov/Archives/edgar/data/2114044/00011931252645441
 4/d22670dex991.htm\nDetails and all sources: https://sec-api.dev/companies
 /coag/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calen
 dar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/coag/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:60f44cdf625ccd9a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Braveheart Bio\, Inc. earnings report (BRVE)
DESCRIPTION:Braveheart Bio\, Inc. earnings report (BRVE): November 10\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "Bravehea
 rt Bio Reports Third Quarter 2026 Financial Results and Provides Business 
 Update" https://www.sec.gov/Archives/edgar/data/2131524/000162828026072702
 /brve-q3268xkex991xearnings.htm\nDetails and all sources: https://sec-api.
 dev/companies/brve/catalysts\nData as of 2026-11-16. sec-api.dev biotech c
 atalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/brve/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:66bb498c0e9daa0b@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Upstream Bio\, Inc. earnings report (UPB)
DESCRIPTION:Upstream Bio\, Inc. earnings report (UPB): November 10\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "Upstream Bi
 o Reports Third Quarter 2026 Financial Results and Highlights Continued Pr
 ogress" https://www.sec.gov/Archives/edgar/data/2022626/000119312526454405
 /upb-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/up
 b/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar 
 (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/upb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6ae8921e51f2b26f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20251110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:INTEGRATED BIOPHARMA INC interim data readout (INBP)
DESCRIPTION:INTEGRATED BIOPHARMA INC interim data readout (INBP): November 
 10\, 2026. Status: scheduled.\nSEC Form 10-Q: "After taking into considera
 tion our interim results and current projections\, management believes tha
 t operations\, together with the revolving credit facility will support ou
 r working capital requirements at least through the period ending November
  10\, 2026." https://www.sec.gov/Archives/edgar/data/1016504/0001437749250
 34076/inbp20250930_10q.htm\nDetails and all sources: https://sec-api.dev/c
 ompanies/inbp/catalysts\nData as of 2026-11-16. sec-api.dev biotech cataly
 st calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/inbp/catalysts
CATEGORIES:interim data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6ca8cc4a69f67199@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Kura Oncology\, Inc. earnings report (KURA)
DESCRIPTION:Kura Oncology\, Inc. earnings report (KURA): November 10\, 2026
 . Status: completed.\nPress release filed with the SEC (EX-99): "Kura Onco
 logy Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE" ht
 tps://www.sec.gov/Archives/edgar/data/1422143/000119312526455416/kura-ex99
 _1.htm\nDetails and all sources: https://sec-api.dev/companies/kura/cataly
 sts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:/
 /sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/kura/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6ce493220e965ec7@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Vireo Growth Inc. earnings report (VREOF)
DESCRIPTION:Vireo Growth Inc. earnings report (VREOF): November 10\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "Vireo Growt
 h Inc. Announces Third Quarter 2026 Results" https://www.sec.gov/Archives/
 edgar/data/1771706/000110465926124793/vreof-ex99d1.htm\nDetails and all so
 urces: https://sec-api.dev/companies/vreof/catalysts\nData as of 2026-11-1
 6. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar
 ).
URL:https://sec-api.dev/companies/vreof/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6f3439b47998ddee@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:IBio\, Inc. earnings report (IBIO)
DESCRIPTION:IBio\, Inc. earnings report (IBIO): November 10\, 2026. Status:
  completed.\nPress release filed with the SEC (EX-99): "Exhibit 99.1 iBio 
 Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Updat
 e" https://www.sec.gov/Archives/edgar/data/1420720/000142072026000035/ibio
 -ex99d1.htm\nDetails and all sources: https://sec-api.dev/companies/ibio/c
 atalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (ht
 tps://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ibio/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:71066b0a4361787c@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Protalix BioTherapeutics\, Inc. earnings report (PLX)
DESCRIPTION:Protalix BioTherapeutics\, Inc. earnings report (PLX): November
  10\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): 
 "CARMIEL\, Israel\, November 10\, 2026 -- Protalix BioTherapeutics\, Inc. 
 (NYSE American:PLX)\, a biopharmaceutical company focused on the discovery
 \, development\, production\, and commercialization of innovative therapeu
 tics for rare diseases with significant unmet needs\, today reported finan
 cial results for the third quarter ended September 30\, 2026\, and provide
 d a business and clinical update." https://www.sec.gov/Archives/edgar/data
 /1006281/000110465926124761/plx-ex99d1.htm\nDetails and all sources: https
 ://sec-api.dev/companies/plx/catalysts\nData as of 2026-11-16. sec-api.dev
  biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/plx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7b40932d9e3d9cf1@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Tyra Biosciences\, Inc. earnings report (TYRA)
DESCRIPTION:Tyra Biosciences\, Inc. earnings report (TYRA): November 10\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Tyra B
 iosciences Reports Third Quarter 2026 Financial Results and Recent Highlig
 hts" https://www.sec.gov/Archives/edgar/data/1863127/000119312526454474/ty
 ra-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/tyra
 /catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (
 https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tyra/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:886ea85914d37cfd@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:MGX-001 earnings report (MGX)
DESCRIPTION:MGX-001 earnings report (MGX): November 10\, 2026. Status: comp
 leted.\nPress release filed with the SEC (EX-99): "Metagenomi Therapeutics
  Announces FDA Clearance of Investigational New Drug Application for MGX-0
 01 and Reports Third Quarter 2026 Financial Results" https://www.sec.gov/A
 rchives/edgar/data/1785279/000119312526455436/mgx-ex99_1.htm\nDetails and 
 all sources: https://sec-api.dev/pdufa/mgx-001\nData as of 2026-11-16. sec
 -api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/mgx-001
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8daead6d750573d3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Cellectar Biosciences\, Inc. earnings report (CLRB)
DESCRIPTION:Cellectar Biosciences\, Inc. earnings report (CLRB): November 1
 0\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "R
 eports Third Quarter 2026 Financial Results and Provides Corporate Updates
 " https://www.sec.gov/Archives/edgar/data/1279704/000110465926124790/tm262
 9430d1_ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/
 clrb/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calend
 ar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/clrb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:996a0dd88e8204d8@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Olema Oncology\, Inc. earnings report (OLMA)
DESCRIPTION:Olema Oncology\, Inc. earnings report (OLMA): November 10\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "SAN FRAN
 CISCO\, November 10\, 2026 (Globe NewsWire) - Olema Pharmaceuticals\, Inc.
  ("Olema" or "Olema Oncology"\, Nasdaq: OLMA)\, a clinical-stage biopharma
 ceutical company focused on the discovery\, development\, and commercializ
 ation of targeted therapies for breast cancer and beyond\, today reported 
 financial and operating results for the third quarter ended September 30\,
  2026." https://www.sec.gov/Archives/edgar/data/1750284/000119312526454403
 /olma-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/o
 lma/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calenda
 r (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/olma/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a058f400ccf14c67@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:BridgeBio Oncology Therapeutics\, Inc. earnings report (BBOT)
DESCRIPTION:BridgeBio Oncology Therapeutics\, Inc. earnings report (BBOT): 
 November 10\, 2026. Status: completed.\nPress release filed with the SEC (
 EX-99): "BBOT Reports Third Quarter 2026 Financial Results and Update on C
 orporate Progress" https://www.sec.gov/Archives/edgar/data/1869105/0001193
 12526455506/bbot-ex99_1.htm\nDetails and all sources: https://sec-api.dev/
 companies/bbot/catalysts\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/bbot/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a39ac40ae2fc7b1b@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Gossamer Bio\, Inc. earnings report (GOSS)
DESCRIPTION:Gossamer Bio\, Inc. earnings report (GOSS): November 10\, 2026.
  Status: completed.\nPress release filed with the SEC (EX-99): "Gossamer B
 io Announces Third Quarter 2026 Financial Results and Provides Business Up
 date" https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/g
 oss-20261110xexx991xearni.htm\nDetails and all sources: https://sec-api.de
 v/companies/goss/catalysts\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/goss/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a621e5174ddf1bd9@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Sionna Therapeutics\, Inc. earnings report (SION)
DESCRIPTION:Sionna Therapeutics\, Inc. earnings report (SION): November 10\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Sio
 nna Therapeutics Reports Third Quarter 2026 Financial Results" https://www
 .sec.gov/Archives/edgar/data/2036042/000162828026072497/sion3q26earningsre
 lease.htm\nDetails and all sources: https://sec-api.dev/companies/sion/cat
 alysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (http
 s://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/sion/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:adede6e3d2c25126@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Symvess (symvess) earnings report (HUMA)
DESCRIPTION:Symvess (symvess) earnings report (HUMA): November 10\, 2026. S
 tatus: completed.\nPress release filed with the SEC (EX-99): "Humacyte Rep
 orts Third Quarter 2026 Results\, Highlighted by More Than Doubling Symves
 s Revenue and Expanding Commercial Adoption" https://www.sec.gov/Archives/
 edgar/data/1818382/000119312526454402/huma-ex99_1.htm\nDetails and all sou
 rces: https://sec-api.dev/pdufa/symvess\nData as of 2026-11-16. sec-api.de
 v biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/symvess
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b1ceebfdfee1c4cd@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:ATOSSA THERAPEUTICS\, INC. earnings report (ATOS)
DESCRIPTION:ATOSSA THERAPEUTICS\, INC. earnings report (ATOS): November 10\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Ato
 ssa Therapeutics Reports Third Quarter 2026 Financial Results and Provides
  a Corporate Update" https://www.sec.gov/Archives/edgar/data/1488039/00011
 9312526454486/atos-ex99_1.htm\nDetails and all sources: https://sec-api.de
 v/companies/atos/catalysts\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/atos/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b61b6aaf60b8db81@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Atara Biotherapeutics\, Inc. earnings report (ATRA)
DESCRIPTION:Atara Biotherapeutics\, Inc. earnings report (ATRA): November 1
 0\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "A
 tara Biotherapeutics Announces Third Quarter 2026 Financial Results and Op
 erational Progress" https://www.sec.gov/Archives/edgar/data/1604464/000110
 465926125171/tmb-ex99d1.htm\nDetails and all sources: https://sec-api.dev/
 companies/atra/catalysts\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/atra/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b9612306a0bfb31a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Liquidia Corp earnings report (LQDA)
DESCRIPTION:Liquidia Corp earnings report (LQDA): November 10\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "- Liquidia Corpo
 ration (NASDAQ: LQDA)\, a biopharmaceutical company driven by science and 
 compassion to revolutionize care for patients with challenging respiratory
  and vascular diseases\, today reported financial results for the third qu
 arter ended September 30\, 2026." https://www.sec.gov/Archives/edgar/data/
 1819576/000110465926124770/tm2629427d1_ex99-1.htm\nDetails and all sources
 : https://sec-api.dev/companies/lqda/catalysts\nData as of 2026-11-16. sec
 -api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/lqda/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bb8922dfbb9a6fdd@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261103T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Karyopharm Therapeutics Inc. PDUFA date (KPTI)
DESCRIPTION:Karyopharm Therapeutics Inc. PDUFA date (KPTI): November 10\, 2
 026. Status: scheduled.\nSEC Form 8-K: "The Company expects to receive a f
 iling communication\, or Day-74 Letter\, from the FDA on or about November
  10\, 2026\, which will include the Prescription Drug User Fee Act target 
 action date and other pertinent information." https://www.sec.gov/Archives
 /edgar/data/1503802/000119312526444164/d141618d8k.htm\nDetails and all sou
 rces: https://sec-api.dev/companies/kpti/catalysts\nData as of 2026-11-16.
  sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/kpti/catalysts
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c7baf94564b1dad5@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:PMV Pharmaceuticals\, Inc. earnings report (PMVP)
DESCRIPTION:PMV Pharmaceuticals\, Inc. earnings report (PMVP): November 10\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "PMV
  Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporat
 e Highlights" https://www.sec.gov/Archives/edgar/data/1699382/000119312526
 454467/pmvp-ex99_1.htm\nDetails and all sources: https://sec-api.dev/compa
 nies/pmvp/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst c
 alendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/pmvp/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c809b573ddbaa0c5@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Opus Genetics\, Inc. earnings report (IRD)
DESCRIPTION:Opus Genetics\, Inc. earnings report (IRD): November 10\, 2026.
  Status: completed.\nPress release filed with the SEC (EX-99): "Opus Genet
 ics Announces Financial Results for" https://www.sec.gov/Archives/edgar/da
 ta/1228627/000162828026072493/ird-20261110xex991.htm\nDetails and all sour
 ces: https://sec-api.dev/companies/ird/catalysts\nData as of 2026-11-16. s
 ec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ird/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c831ed638d00f65d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Release (release) complete response letter (CRL) (CING)
DESCRIPTION:Release (release) complete response letter (CRL) (CING): Novemb
 er 10\, 2026. Status: completed (crl).\nSEC Form 8-K: "November 10\, 2026\
 , Cingulate Inc. (Company) issued a press release announcing that its Chai
 rman and CEO\, Shane J. Schaffer\, in an interview on Innovators with Jane
  King discusses the Company's ongoing efforts to address the U.S. Food and
  Drug Administration's (FDA) Complete Response Letter (CRL) regarding the 
 CTx-1301 new drug application (NDA)\, progress made to date\, and the anti
 cipated timeline for NDA resubmission." https://www.sec.gov/Archives/edgar
 /data/1862150/000149315226050870/form8-k.htm\nDetails and all sources: htt
 ps://sec-api.dev/pdufa/release\nData as of 2026-11-16. sec-api.dev biotech
  catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/release
CATEGORIES:complete response letter (CRL)
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cae1ac04f2e694e8@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Gain Therapeutics\, Inc. earnings report (GANX)
DESCRIPTION:Gain Therapeutics\, Inc. earnings report (GANX): November 10\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Gain 
 Therapeutics Reports Financial Results for Third Quarter 2026 and Provides
  Corporate Update" https://www.sec.gov/Archives/edgar/data/1819411/0001104
 65926125159/ganx-ex99d1.htm\nDetails and all sources: https://sec-api.dev/
 companies/ganx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ganx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d2b3ffd39595eabf@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:INOVIO PHARMACEUTICALS\, INC. earnings report (INO)
DESCRIPTION:INOVIO PHARMACEUTICALS\, INC. earnings report (INO): November 1
 0\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "I
 NOVIO Reports Third Quarter 2026 Financial Results and Recent Business Hig
 hlights" https://www.sec.gov/Archives/edgar/data/1055726/00010557262600003
 0/ino-93026x8kex991.htm\nDetails and all sources: https://sec-api.dev/comp
 anies/ino/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst c
 alendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ino/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d457f82ea04f94c3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:PepGen Inc. earnings report (PEPG)
DESCRIPTION:PepGen Inc. earnings report (PEPG): November 10\, 2026. Status:
  completed.\nPress release filed with the SEC (EX-99): "PepGen Reports Thi
 rd Quarter 2026 Financial Results and Recent Corporate Highlights" https:/
 /www.sec.gov/Archives/edgar/data/1835597/000119312526454469/pepg-ex99_1.ht
 m\nDetails and all sources: https://sec-api.dev/companies/pepg/catalysts\n
 Data as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-
 api.dev/fda-calendar).
URL:https://sec-api.dev/companies/pepg/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:da374fcba2ea84d5@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20260916T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:NRX Pharmaceuticals\, Inc. PDUFA date (NRXP)
DESCRIPTION:NRX Pharmaceuticals\, Inc. PDUFA date (NRXP): November 10\, 202
 6. Status: scheduled.\nSEC Form 8-K: "The acknowledgement letter revised t
 he GDUFA goal date to November 10\, 2026\, citing that the reclassified am
 endment will not require a substantial expenditure of FDA resources." http
 s://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/nrxp2026091
 5_8k.htm\nDetails and all sources: https://sec-api.dev/companies/nrxp/cata
 lysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https
 ://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/nrxp/catalysts
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dcfd279909c3b0f6@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Imatinib earnings report (IKT)
DESCRIPTION:Imatinib earnings report (IKT): November 10\, 2026. Status: com
 pleted.\nPress release filed with the SEC (EX-99): ""Company")\, a clinica
 l-stage pharmaceutical company developing IKT-001\, a novel once-daily ora
 l anti-proliferative for Pulmonary Arterial Hypertension ("PAH")\, today r
 eported financial results for the quarter ended September 30\, 2026\, and 
 highlighted recent developments." https://www.sec.gov/Archives/edgar/data/
 1750149/000119312526455560/d95716dex991.htm\nDetails and all sources: http
 s://sec-api.dev/pdufa/imatinib\nData as of 2026-11-16. sec-api.dev biotech
  catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/imatinib
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e766dbf07656479d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Arbutus Biopharma Corp earnings report (ABUS)
DESCRIPTION:Arbutus Biopharma Corp earnings report (ABUS): November 10\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Arbutus
  Reports Third Quarter 2026 Financial Results and Provides Corporate Updat
 e" https://www.sec.gov/Archives/edgar/data/1447028/000117184326007311/exh_
 991.htm\nDetails and all sources: https://sec-api.dev/companies/abus/catal
 ysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:
 //sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/abus/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f054f883cea6d247@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:PepGen Inc. topline data readout (PEPG)
DESCRIPTION:PepGen Inc. topline data readout (PEPG): November 10\, 2026. St
 atus: completed (positive).\nPress release filed with the SEC (EX-99): "BO
 STON-- November 10\, 2026-- PepGen Inc. (Nasdaq: PEPG)\, a clinical-stage 
 biotechnology company pioneering oligonucleotide therapies with the potent
 ial to transform the treatment of rare genetic diseases\, today announced 
 positive topline results from the 10 mg/kg multiple ascending dose cohort 
 of the ongoing Phase 2 FREEDOM2-DM1 trial (NCT06667453) evaluating PGN-EDO
 DM1 in patients with myotonic dystrophy type 1 (DM1)\, a rare\, progressiv
 e\, and multisystemic genetic disease." https://www.sec.gov/Archives/edgar
 /data/1835597/000119312526454469/pepg-ex99_2.htm\nDetails and all sources:
  https://sec-api.dev/companies/pepg/catalysts\nData as of 2026-11-16. sec-
 api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/pepg/catalysts
CATEGORIES:topline data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f06db8fb9c82123a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Veradermics\, Inc earnings report (MANE)
DESCRIPTION:Veradermics\, Inc earnings report (MANE): November 10\, 2026. S
 tatus: completed.\nPress release filed with the SEC (EX-99): "Veradermics 
 Reports Third Quarter 2026 Financial Results and Highlights Recent Corpora
 te and Clinical Progress" https://www.sec.gov/Archives/edgar/data/1827635/
 000182763526000041/ex991q326earnings.htm\nDetails and all sources: https:/
 /sec-api.dev/companies/mane/catalysts\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mane/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f758e91b1ed615af@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:Zulresso (brexanolone) trial start (LPCN)
DESCRIPTION:Zulresso (brexanolone) trial start (LPCN): November 10\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "LAKE CITY\,
  November 10\, 2026 — Lipocine Inc. (NASDAQ: LPCN)\, a specialty pharmac
 eutical company focused on the development of novel oral therapeutics\, to
 day announced that the first participant has been dosed in BLOOM\, the Com
 pany's Phase 3 study evaluating" https://www.sec.gov/Archives/edgar/data/1
 535955/000149315226050842/ex99-1.htm\nDetails and all sources: https://sec
 -api.dev/pdufa/brexanolone\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/brexanolone
CATEGORIES:trial start
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fa72fcabd4601785@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:CUMBERLAND PHARMACEUTICALS INC earnings report (CPIX)
DESCRIPTION:CUMBERLAND PHARMACEUTICALS INC earnings report (CPIX): November
  10\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): 
 "(Nov. 10\, 2026) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX)\, an in
 novation-focused biopharmaceutical company developing new products for rar
 e diseases\, announced today its third quarter 2026 financial results and 
 provided a company update." https://www.sec.gov/Archives/edgar/data/108729
 4/000108729426000076/a2026q3-ex991er.htm\nDetails and all sources: https:/
 /sec-api.dev/companies/cpix/catalysts\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cpix/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:nct07226752-readout@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261116T102001Z
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261111
SUMMARY:TEPKINLY (epcoritamab) topline data readout (GMAB)
DESCRIPTION:TEPKINLY (epcoritamab) topline data readout (GMAB): November 10
 \, 2026. Status: completed.\nClinicalTrials.gov: "NCT07226752 (A Sub-study
  Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Re
 fractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Stat
 us ACTIVE_NOT_RECRUITING\; Phase PHASE3\; Primary Completion 2025-10-13 (A
 CTUAL)\; Lead Sponsor Genmab\; Results First Posted 2026-11-10." https://c
 linicaltrials.gov/study/NCT07226752?tab=results\nDetails and all sources: 
 https://sec-api.dev/pdufa/epcoritamab\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/epcoritamab
CATEGORIES:topline data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0380bae49a715dab@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Kardigan\, Inc. earnings report (KARD)
DESCRIPTION:Kardigan\, Inc. earnings report (KARD): November 12\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "Kardigan Repor
 ts Third Quarter 2026 Financial Results and Recent Business Updates" https
 ://www.sec.gov/Archives/edgar/data/2123613/000119312526456885/ck0002123613
 -ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/kard/c
 atalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (ht
 tps://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/kard/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:06b34c6b1b980968@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:TScan Therapeutics\, Inc. earnings report (TCRX)
DESCRIPTION:TScan Therapeutics\, Inc. earnings report (TCRX): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "TSca
 n Therapeutics Reports Third Quarter 2026 Financial Results and Provides C
 orporate Update" https://www.sec.gov/Archives/edgar/data/1783328/000119312
 526456865/tcrx-ex99_1.htm\nDetails and all sources: https://sec-api.dev/co
 mpanies/tcrx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tcrx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:08dbe78ec0a60294@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Bolt Biotherapeutics\, Inc. earnings report (BOLT)
DESCRIPTION:Bolt Biotherapeutics\, Inc. earnings report (BOLT): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Bo
 lt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provid
 es Business Update" https://www.sec.gov/Archives/edgar/data/1641281/000119
 312526458403/bolt-ex99_1.htm\nDetails and all sources: https://sec-api.dev
 /companies/bolt/catalysts\nData as of 2026-11-16. sec-api.dev biotech cata
 lyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/bolt/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0d78b876d72f5f4d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Akari Therapeutics Plc earnings report (AKTX)
DESCRIPTION:Akari Therapeutics Plc earnings report (AKTX): November 12\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Therape
 utics Reports Third Quarter 2026 Financial Results and Highlights Continue
 d Progress Toward Clinical Development of Differentiated" https://www.sec.
 gov/Archives/edgar/data/1541157/000149315226051486/ex99-1.htm\nDetails and
  all sources: https://sec-api.dev/companies/aktx/catalysts\nData as of 202
 6-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-ca
 lendar).
URL:https://sec-api.dev/companies/aktx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0db0a8ff69fb7e1e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Spero Therapeutics\, Inc. earnings report (SPRO)
DESCRIPTION:Spero Therapeutics\, Inc. earnings report (SPRO): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "CAMB
 RIDGE\, Mass.\, November 12\, 2026 - Spero Therapeutics\, Inc. (Nasdaq: SP
 RO)\, a clinical-stage biopharmaceutical company focused on advancing next
 -generation medicines for immune-mediated diseases\, today announced finan
 cial results for the third quarter ended September 30\, 2026\, and provide
 d a business update." https://www.sec.gov/Archives/edgar/data/1701108/0001
 19312526458637/spro-ex99_1.htm\nDetails and all sources: https://sec-api.d
 ev/companies/spro/catalysts\nData as of 2026-11-16. sec-api.dev biotech ca
 talyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/spro/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:11c76c5cae75b544@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Parabilis Medicines\, Inc. earnings report (PBLS)
DESCRIPTION:Parabilis Medicines\, Inc. earnings report (PBLS): November 12\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Par
 abilis Medicines Reports Third Quarter 2026 Financial Results and Provides
  Business Updates" https://www.sec.gov/Archives/edgar/data/1657677/0001193
 12526456892/ck0001657677-ex99_1.htm\nDetails and all sources: https://sec-
 api.dev/companies/pbls/catalysts\nData as of 2026-11-16. sec-api.dev biote
 ch catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/pbls/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1271ff7d6d283030@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Ensysce Biosciences\, Inc. earnings report (ENSC)
DESCRIPTION:Ensysce Biosciences\, Inc. earnings report (ENSC): November 12\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Bio
 sciences Reports Third Quarter 2026 Financial Results and Business Highlig
 hts" https://www.sec.gov/Archives/edgar/data/1716947/000149315226051414/ex
 99-1.htm\nDetails and all sources: https://sec-api.dev/companies/ensc/cata
 lysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https
 ://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ensc/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1358cc307004c9c1@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Aglatimagene trial start (CADL)
DESCRIPTION:Aglatimagene trial start (CADL): November 12\, 2026. Status: co
 mpleted.\nPress release filed with the SEC (EX-99): "As previously announc
 ed\, the Company initiated the first clinical trial site of the global piv
 otal phase 3 clinical trial (AURORA) (NCT07660094)\, which is evaluating a
 glatimagene plus valacyclovir in combination with continued pembrolizumab 
 in patients with metastatic non-squamous NSCLC whose disease has progresse
 d despite treatment with pembrolizumab and platinum-based chemotherapy." h
 ttps://www.sec.gov/Archives/edgar/data/1841387/000119312526458316/cadl-ex9
 9_1.htm\nDetails and all sources: https://sec-api.dev/pdufa/aglatimagene\n
 Data as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-
 api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/aglatimagene
CATEGORIES:trial start
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:184158ca8cc8f4e5@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:BioCardia\, Inc. earnings report (BCDA)
DESCRIPTION:BioCardia\, Inc. earnings report (BCDA): November 12\, 2026. St
 atus: completed.\nPress release filed with the SEC (EX-99): "BioCardia Rep
 orts Third Quarter 2026 Business Highlights and Financial Results" https:/
 /www.sec.gov/Archives/edgar/data/925741/000143774926036574/ex_1044180.htm\
 nDetails and all sources: https://sec-api.dev/companies/bcda/catalysts\nDa
 ta as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-ap
 i.dev/fda-calendar).
URL:https://sec-api.dev/companies/bcda/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1c157fdeccdf3cc9@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:TALPHERA\, INC. earnings report (TLPH)
DESCRIPTION:TALPHERA\, INC. earnings report (TLPH): November 12\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "Talphera Repor
 ts Third Quarter 2026 Financial Results and Provides Business Update" http
 s://www.sec.gov/Archives/edgar/data/1427925/000143774926036555/ex_1043772.
 htm\nDetails and all sources: https://sec-api.dev/companies/tlph/catalysts
 \nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://se
 c-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tlph/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1cdcbe74931580a6@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ProMIS Neurosciences Inc. earnings report (PMN)
DESCRIPTION:ProMIS Neurosciences Inc. earnings report (PMN): November 12\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "ProMI
 S Neurosciences Announces Third Quarter 2026 Financial Results and Reaffir
 ms First Quarter 2027 Topline Data Timing" https://www.sec.gov/Archives/ed
 gar/data/1374339/000110465926126260/pmn-ex99d1.htm\nDetails and all source
 s: https://sec-api.dev/companies/pmn/catalysts\nData as of 2026-11-16. sec
 -api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/pmn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1d097c50bfba22f3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Armata Pharmaceuticals\, Inc. earnings report (ARMP)
DESCRIPTION:Armata Pharmaceuticals\, Inc. earnings report (ARMP): November 
 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "
 Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2
 026 and Provides Corporate Update" https://www.sec.gov/Archives/edgar/data
 /921114/000110465926126274/armp-ex99d1.htm\nDetails and all sources: https
 ://sec-api.dev/companies/armp/catalysts\nData as of 2026-11-16. sec-api.de
 v biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/armp/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:23add8f5c8f259a0@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ARROWHEAD PHARMACEUTICALS\, INC. earnings report (ARWR)
DESCRIPTION:ARROWHEAD PHARMACEUTICALS\, INC. earnings report (ARWR): Novemb
 er 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99)
 : "Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results" https:/
 /www.sec.gov/Archives/edgar/data/879407/000087940726000077/arwr-202611128k
 ex991.htm\nDetails and all sources: https://sec-api.dev/companies/arwr/cat
 alysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (http
 s://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/arwr/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:251cc3862d234cb2@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Eikon Therapeutics\, Inc. earnings report (EIKN)
DESCRIPTION:Eikon Therapeutics\, Inc. earnings report (EIKN): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Eiko
 n Therapeutics Reports Third Quarter 2026 Financial Results and Provides C
 linical Updates" https://www.sec.gov/Archives/edgar/data/1861123/000119312
 526456794/eikn-ex99_1.htm\nDetails and all sources: https://sec-api.dev/co
 mpanies/eikn/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/eikn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:25761a3df6ce821e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Serina Therapeutics\, Inc. earnings report (SER)
DESCRIPTION:Serina Therapeutics\, Inc. earnings report (SER): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Seri
 na Therapeutics Reports Third Quarter 2026 Financial Results and Provides 
 Business Updates" https://www.sec.gov/Archives/edgar/data/1708599/00017085
 9926000069/ser-20261112xex991_earning.htm\nDetails and all sources: https:
 //sec-api.dev/companies/ser/catalysts\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ser/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:258c586a07ac5b4d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Generate Biomedicines\, Inc. earnings report (GENB)
DESCRIPTION:Generate Biomedicines\, Inc. earnings report (GENB): November 1
 2\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "G
 enerate Biomedicines Reports Third Quarter 2026 Financial Results and Prov
 ides Business Update" https://www.sec.gov/Archives/edgar/data/2100782/0001
 19312526456921/ck0002100782-ex99_1.htm\nDetails and all sources: https://s
 ec-api.dev/companies/genb/catalysts\nData as of 2026-11-16. sec-api.dev bi
 otech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/genb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:25942eb493886221@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Yarrow Bioscience\, Inc. earnings report (YARW)
DESCRIPTION:Yarrow Bioscience\, Inc. earnings report (YARW): November 12\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Yarro
 w Bioscience Reports Third Quarter 2026 Financial Results and Provides Bus
 iness Update" https://www.sec.gov/Archives/edgar/data/1566044/000156604426
 000017/yarw-q32026earningsrelease.htm\nDetails and all sources: https://se
 c-api.dev/companies/yarw/catalysts\nData as of 2026-11-16. sec-api.dev bio
 tech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/yarw/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2df60ced576bf2f8@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Equillium\, Inc. earnings report (EQ)
DESCRIPTION:Equillium\, Inc. earnings report (EQ): November 12\, 2026. Stat
 us: completed.\nPress release filed with the SEC (EX-99): "Equillium Repor
 ts Third Quarter 2026 Financial Results and Recent Corporate and Clinical 
 Highlights" https://www.sec.gov/Archives/edgar/data/1746466/00011931252645
 8379/eq-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies
 /eq/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calenda
 r (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/eq/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2f7d16a27b78e1cc@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Prime Medicine\, Inc. earnings report (PRME)
DESCRIPTION:Prime Medicine\, Inc. earnings report (PRME): November 12\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "Prime Me
 dicine Reports Third Quarter 2026 Financial Results and Provides Business 
 Updates" https://www.sec.gov/Archives/edgar/data/1894562/00016282802607337
 2/q320268-kex991xpressrelease.htm\nDetails and all sources: https://sec-ap
 i.dev/companies/prme/catalysts\nData as of 2026-11-16. sec-api.dev biotech
  catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/prme/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:342ed1fd3b1cf51f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:DYADIC INTERNATIONAL INC earnings report (DYAI)
DESCRIPTION:DYADIC INTERNATIONAL INC earnings report (DYAI): November 12\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "ANNOU
 NCES THIRD QUARTER 2026 FINANCIAL RESULTS AND RECENT DEVELOPMENTS" https:/
 /www.sec.gov/Archives/edgar/data/1213809/000149315226051601/ex99-1.htm\nDe
 tails and all sources: https://sec-api.dev/companies/dyai/catalysts\nData 
 as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.d
 ev/fda-calendar).
URL:https://sec-api.dev/companies/dyai/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:38b3233161632928@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Avalyn Pharma Inc. earnings report (AVLN)
DESCRIPTION:Avalyn Pharma Inc. earnings report (AVLN): November 12\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "Avalyn Repo
 rts Third Quarter 2026 Financial Results and Recent Business Highlights" h
 ttps://www.sec.gov/Archives/edgar/data/1540171/000119312526457053/ck000154
 0171-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/av
 ln/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar
  (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/avln/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3a24b5db3910b60f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Kyverna Therapeutics\, Inc. earnings report (KYTX)
DESCRIPTION:Kyverna Therapeutics\, Inc. earnings report (KYTX): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Ky
 verna Therapeutics Announces Completion of BLA Submission for Miv-cel in S
 tiff Person Syndrome and Reports Third Quarter 2026 Financial Results" htt
 ps://www.sec.gov/Archives/edgar/data/1994702/000119312526457040/kytx-ex99_
 1.htm\nDetails and all sources: https://sec-api.dev/companies/kytx/catalys
 ts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://
 sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/kytx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3c4ec2e04c29cf46@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Evommune\, Inc. earnings report (EVMN)
DESCRIPTION:Evommune\, Inc. earnings report (EVMN): November 12\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "Evommune Repor
 ts Third Quarter 2026 Financial Results and Provides Business Highlights" 
 https://www.sec.gov/Archives/edgar/data/2044725/000119312526458329/evmn-ex
 99_1.htm\nDetails and all sources: https://sec-api.dev/companies/evmn/cata
 lysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https
 ://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/evmn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3e4fdd27746aaed3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Journey Medical Corp earnings report (DERM)
DESCRIPTION:Journey Medical Corp earnings report (DERM): November 12\, 2026
 . Status: completed.\nPress release filed with the SEC (EX-99): "Corporati
 on Reports Third Quarter 2026 Financial Results and Recent Corporate Highl
 ights" https://www.sec.gov/Archives/edgar/data/1867066/000110465926126209/
 tm2629579d1_ex99-1.htm\nDetails and all sources: https://sec-api.dev/compa
 nies/derm/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst c
 alendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/derm/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3ee96fccd3c33928@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:CRESCENT BIOPHARMA\, INC. earnings report (CBIO)
DESCRIPTION:CRESCENT BIOPHARMA\, INC. earnings report (CBIO): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Cres
 cent Biopharma Reports Third Quarter 2026 Financial Results and Recent Bus
 iness Highlights" https://www.sec.gov/Archives/edgar/data/1253689/00016282
 8026073409/pressrelease-livefile.htm\nDetails and all sources: https://sec
 -api.dev/companies/cbio/catalysts\nData as of 2026-11-16. sec-api.dev biot
 ech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cbio/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3fef8c324767f471@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:MeiraGTx Holdings plc earnings report (MGTX)
DESCRIPTION:MeiraGTx Holdings plc earnings report (MGTX): November 12\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "LONDON a
 nd NEW YORK\, November 12\, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc
  (Nasdaq: MGTX)\, a vertically integrated\, clinical stage genetic medicin
 es company\, today announced financial and operational results for the thi
 rd quarter ended September 30\, 2026\, and provided a corporate update." h
 ttps://www.sec.gov/Archives/edgar/data/1735438/000110465926125910/mgtx-ex9
 9d1.htm\nDetails and all sources: https://sec-api.dev/companies/mgtx/catal
 ysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:
 //sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mgtx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:414d41acf07134ac@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ROCKET PHARMACEUTICALS\, INC. earnings report (RCKT)
DESCRIPTION:ROCKET PHARMACEUTICALS\, INC. earnings report (RCKT): November 
 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "
 Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and" h
 ttps://www.sec.gov/Archives/edgar/data/1281895/000114036126043434/ef200854
 55_ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/rckt
 /catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (
 https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/rckt/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4b1a6f4975fcb1ba@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:PLIANT THERAPEUTICS\, INC. earnings report (PLRX)
DESCRIPTION:PLIANT THERAPEUTICS\, INC. earnings report (PLRX): November 12\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Pli
 ant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 
 Financial Results" https://www.sec.gov/Archives/edgar/data/1746473/0001746
 47326000127/plrx-20261112xexx991.htm\nDetails and all sources: https://sec
 -api.dev/companies/plrx/catalysts\nData as of 2026-11-16. sec-api.dev biot
 ech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/plrx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4bb16d6db8c72db6@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Verrica Pharmaceuticals Inc. earnings report (VRCA)
DESCRIPTION:Verrica Pharmaceuticals Inc. earnings report (VRCA): November 1
 2\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "V
 errica Pharmaceuticals Reports Third Quarter 2026 Financial Results" https
 ://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex99
 1.htm\nDetails and all sources: https://sec-api.dev/companies/vrca/catalys
 ts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://
 sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/vrca/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4cf095d0053fef6e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Silence Therapeutics plc earnings report (SLN)
DESCRIPTION:Silence Therapeutics plc earnings report (SLN): November 12\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Silenc
 e Therapeutics Highlights Recent Business Achievements and Reports Third Q
 uarter 2026 Financial Results" https://www.sec.gov/Archives/edgar/data/147
 9615/000119312526457060/d101909dex991.htm\nDetails and all sources: https:
 //sec-api.dev/companies/sln/catalysts\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/sln/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4f881a4a26aeac5d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:BlossomHill Therapeutics\, Inc. earnings report (BLSM)
DESCRIPTION:BlossomHill Therapeutics\, Inc. earnings report (BLSM): Novembe
 r 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99):
  "BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results an
 d Recent Business Highlights" https://www.sec.gov/Archives/edgar/data/1839
 970/000119312526458447/d389211dex991.htm\nDetails and all sources: https:/
 /sec-api.dev/companies/blsm/catalysts\nData as of 2026-11-16. sec-api.dev 
 biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/blsm/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4fd0521b830cd461@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Candel Therapeutics\, Inc. earnings report (CADL)
DESCRIPTION:Candel Therapeutics\, Inc. earnings report (CADL): November 12\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Can
 del Therapeutics Reports Third Quarter 2026 Financial Results and Recent C
 orporate Highlights" https://www.sec.gov/Archives/edgar/data/1841387/00011
 9312526458316/cadl-ex99_1.htm\nDetails and all sources: https://sec-api.de
 v/companies/cadl/catalysts\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cadl/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:50b7e76c02f42022@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ROCKWELL MEDICAL\, INC. earnings report (RMTI)
DESCRIPTION:ROCKWELL MEDICAL\, INC. earnings report (RMTI): November 12\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Rockwe
 ll Medical Announces Third Quarter 2026 Results" https://www.sec.gov/Archi
 ves/edgar/data/1041024/000162828026073052/a2026q326-earningsxpr.htm\nDetai
 ls and all sources: https://sec-api.dev/companies/rmti/catalysts\nData as 
 of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/
 fda-calendar).
URL:https://sec-api.dev/companies/rmti/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:552941e79cb12aba@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Taysha Gene Therapies\, Inc. earnings report (TSHA)
DESCRIPTION:Taysha Gene Therapies\, Inc. earnings report (TSHA): November 1
 2\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "T
 aysha Gene Therapies Reports Third Quarter 2026 Financial Results and Prov
 ides Corporate Update" https://www.sec.gov/Archives/edgar/data/1806310/000
 119312526456974/d497108dex991.htm\nDetails and all sources: https://sec-ap
 i.dev/companies/tsha/catalysts\nData as of 2026-11-16. sec-api.dev biotech
  catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tsha/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5576a821ff89146f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Sagimet Biosciences Inc. earnings report (SGMT)
DESCRIPTION:Sagimet Biosciences Inc. earnings report (SGMT): November 12\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Sagim
 et Biosciences Reports Third Quarter 2026 Financial Results and Provides C
 orporate Updates" https://www.sec.gov/Archives/edgar/data/1400118/00011931
 2526457000/d123481dex991.htm\nDetails and all sources: https://sec-api.dev
 /companies/sgmt/catalysts\nData as of 2026-11-16. sec-api.dev biotech cata
 lyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/sgmt/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5bcb5c28369f342d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Absci Corp earnings report (ABSI)
DESCRIPTION:Absci Corp earnings report (ABSI): November 12\, 2026. Status: 
 completed.\nPress release filed with the SEC (EX-99): "VANCOUVER\, Wash. a
 nd NEW YORK\, November 12\, 2026 - Absci Corporation (Nasdaq: ABSI)\, a cl
 inical-stage biopharmaceutical company advancing breakthrough therapeutics
  designed with generative AI\, today reported financial and operating resu
 lts for the quarter ended September 30\, 2026." https://www.sec.gov/Archiv
 es/edgar/data/1672688/000167268826000150/exhibit991-2026q310xqpr.htm\nDeta
 ils and all sources: https://sec-api.dev/companies/absi/catalysts\nData as
  of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev
 /fda-calendar).
URL:https://sec-api.dev/companies/absi/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:679ec8b80f8a961c@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:KIORA PHARMACEUTICALS INC earnings report (KPRX)
DESCRIPTION:KIORA PHARMACEUTICALS INC earnings report (KPRX): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Kior
 a Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provide
 s Corporate Update" https://www.sec.gov/Archives/edgar/data/1372514/000137
 251426000093/ex991-pressreleaseseptembe.htm\nDetails and all sources: http
 s://sec-api.dev/companies/kprx/catalysts\nData as of 2026-11-16. sec-api.d
 ev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/kprx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6a55a7504afaaf1a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Emavusertib earnings report (CRIS)
DESCRIPTION:Emavusertib earnings report (CRIS): November 12\, 2026. Status:
  completed.\nPress release filed with the SEC (EX-99): "-- Curis\, Inc. (N
 ASDAQ: CRIS)\, a biotechnology company focused on the development of emavu
 sertib (CA-4948)\, an orally available\, small molecule IRAK4 and FLT3 inh
 ibitor\, today reported its financial and operating results for the third 
 quarter ended September 30\," https://www.sec.gov/Archives/edgar/data/1108
 205/000110465926127041/tm2629651d1_ex99-1.htm\nDetails and all sources: ht
 tps://sec-api.dev/pdufa/emavusertib\nData as of 2026-11-16. sec-api.dev bi
 otech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/emavusertib
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:728b4dd50b2f0848@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Obsidian Therapeutics\, Inc. earnings report (OBX)
DESCRIPTION:Obsidian Therapeutics\, Inc. earnings report (OBX): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Ob
 sidian Therapeutics Reports Third Quarter 2026 Financial Results and Busin
 ess Updates" https://www.sec.gov/Archives/edgar/data/2130606/0001193125264
 58347/d20599dex991.htm\nDetails and all sources: https://sec-api.dev/compa
 nies/obx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst ca
 lendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/obx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:752114ae619f7888@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:NEKTAR THERAPEUTICS earnings report (NKTR)
DESCRIPTION:NEKTAR THERAPEUTICS earnings report (NKTR): November 12\, 2026.
  Status: completed.\nPress release filed with the SEC (EX-99): "PRESS RELE
 ASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2026 RESULTS."" http
 s://www.sec.gov/Archives/edgar/data/906709/000121390026118964/ea031199801e
 x99-1.htm\nDetails and all sources: https://sec-api.dev/companies/nktr/cat
 alysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (http
 s://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/nktr/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7b9944e69701c9a0@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ADARx Pharmaceuticals\, Inc. earnings report (ADRX)
DESCRIPTION:ADARx Pharmaceuticals\, Inc. earnings report (ADRX): November 1
 2\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "A
 DARx Reports Third Quarter 2026 Financial Results and Provides Business Up
 dates" https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/
 adrx-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/ad
 rx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar
  (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/adrx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7f6451aade9547a5@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Longeveron Inc. earnings report (LGVN)
DESCRIPTION:Longeveron Inc. earnings report (LGVN): November 12\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "Following repo
 rting of results for the ELPIS II Phase 2b clinical trial\, the Company ha
 s requested a meeting with the FDA to review the results to determine pote
 ntial next steps for the HLHS development program" https://www.sec.gov/Arc
 hives/edgar/data/1721484/000121390026119052/ea031194401ex99-1.htm\nDetails
  and all sources: https://sec-api.dev/companies/lgvn/catalysts\nData as of
  2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fd
 a-calendar).
URL:https://sec-api.dev/companies/lgvn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8b15fe3b1f8054e0@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:REVIVA PHARMACEUTICALS HOLDINGS\, INC. earnings report (RVPH)
DESCRIPTION:REVIVA PHARMACEUTICALS HOLDINGS\, INC. earnings report (RVPH): 
 November 12\, 2026. Status: completed.\nPress release filed with the SEC (
 EX-99): "Reviva Reports Third Quarter 2026 Financial Results and Recent Bu
 siness Highlights" https://www.sec.gov/Archives/edgar/data/1742927/0001437
 74926036647/ex_1042036.htm\nDetails and all sources: https://sec-api.dev/c
 ompanies/rvph/catalysts\nData as of 2026-11-16. sec-api.dev biotech cataly
 st calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/rvph/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8bf4b84087d0911d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Erasca\, Inc. earnings report (ERAS)
DESCRIPTION:Erasca\, Inc. earnings report (ERAS): November 12\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "Erasca Reports T
 hird Quarter 2026 Business Updates and Financial Results" https://www.sec.
 gov/Archives/edgar/data/1761918/000119312526458350/eras-ex99_1.htm\nDetail
 s and all sources: https://sec-api.dev/companies/eras/catalysts\nData as o
 f 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/f
 da-calendar).
URL:https://sec-api.dev/companies/eras/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:929599b173efbd69@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Immix Biopharma\, Inc. earnings report (IMMX)
DESCRIPTION:Immix Biopharma\, Inc. earnings report (IMMX): November 12\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Biophar
 ma Reports Third Quarter 2026 Financial Results and Update on Corporate Pr
 ogress" https://www.sec.gov/Archives/edgar/data/1873835/000149315226051402
 /ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/immx/c
 atalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (ht
 tps://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/immx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:971e7bee8329c3e9@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Azora Therapeutics\, Inc. (DE) earnings report (AZR)
DESCRIPTION:Azora Therapeutics\, Inc. (DE) earnings report (AZR): November 
 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "
 -- Azora Therapeutics\, Inc. (Nasdaq: AZR) ("Azora" or the "Company")\, a 
 biopharmaceutical company developing locally acting treatments for serious
  immune-mediated and inflammatory diseases\, today provided a business upd
 ate and reported its financial results for the third quarter ended Septemb
 er 30\, 2026." https://www.sec.gov/Archives/edgar/data/1513525/00012139002
 6118922/ea031195201ex99-1.htm\nDetails and all sources: https://sec-api.de
 v/companies/azr/catalysts\nData as of 2026-11-16. sec-api.dev biotech cata
 lyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/azr/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9923acf90ca9c8bd@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:RELMADA THERAPEUTICS\, INC. earnings report (RLMD)
DESCRIPTION:RELMADA THERAPEUTICS\, INC. earnings report (RLMD): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Re
 ports Third Quarter 2026 Financial Results and Provides Business Update" h
 ttps://www.sec.gov/Archives/edgar/data/1553643/000121390026118933/ea031205
 701ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/rlmd
 /catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (
 https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/rlmd/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9a6f8ff518742f1a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Azitra\, Inc. earnings report (AZTR)
DESCRIPTION:Azitra\, Inc. earnings report (AZTR): November 12\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "BRANFORD\, Conn.
  - November 12\, 2026 — Azitra\, Inc. ("Azitra" or the "Company") (NYSE 
 American: AZTR)\, a clinical stage biopharmaceutical company focused on de
 veloping innovative therapies for precision dermatology and high value cos
 metic proteins and peptides\, today reported financial results for the qua
 rter ended September 30\, 2026\, and provided a business update." https://
 www.sec.gov/Archives/edgar/data/1701478/000170147826000051/aztrpressreleas
 e9302026-ex.htm\nDetails and all sources: https://sec-api.dev/companies/az
 tr/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar
  (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/aztr/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9b2c23bd5a718770@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:MiNK Therapeutics\, Inc. earnings report (INKT)
DESCRIPTION:MiNK Therapeutics\, Inc. earnings report (INKT): November 12\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "MiNK 
 Therapeutics Reports Third Quarter 2026 Results\, First Pre-Commercial Pro
 duct Revenue from agenT-797\, Randomized ARDS Trial Advancing\, and ARPA-H
  Selection for Deployable Cell Therapies" https://www.sec.gov/Archives/edg
 ar/data/1840229/000119312526457244/inkt-ex99_1.htm\nDetails and all source
 s: https://sec-api.dev/companies/inkt/catalysts\nData as of 2026-11-16. se
 c-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/inkt/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a629876b1178dfaf@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Kodiak Sciences Inc. earnings report (KOD)
DESCRIPTION:Kodiak Sciences Inc. earnings report (KOD): November 12\, 2026.
  Status: completed.\nPress release filed with the SEC (EX-99): "Kodiak Sci
 ences Announces Recent Business Highlights and Third Quarter 2026 Financia
 l Results" https://www.sec.gov/Archives/edgar/data/1468748/000119312526458
 248/kod-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies
 /kod/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calend
 ar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/kod/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a632b163f69a3f2e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ASSEMBLY BIOSCIENCES\, INC. earnings report (ASMB)
DESCRIPTION:ASSEMBLY BIOSCIENCES\, INC. earnings report (ASMB): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "As
 sembly Biosciences Reports Third Quarter 2026 Financial Results and Recent
  Updates" https://www.sec.gov/Archives/edgar/data/1426800/0001193125264583
 14/asmb-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies
 /asmb/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calen
 dar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/asmb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a9b81a76f57072c0@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Twist Bioscience Corp earnings report (TWST)
DESCRIPTION:Twist Bioscience Corp earnings report (TWST): November 12\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "Twist Bi
 oscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial
  Results" https://www.sec.gov/Archives/edgar/data/1581280/0001581280260000
 53/twst-2026930xex991.htm\nDetails and all sources: https://sec-api.dev/co
 mpanies/twst/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/twst/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a9be9acf31bbdaf3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Eledon Pharmaceuticals\, Inc. earnings report (ELDN)
DESCRIPTION:Eledon Pharmaceuticals\, Inc. earnings report (ELDN): November 
 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "
 Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Re
 cent Business Highlights" https://www.sec.gov/Archives/edgar/data/1404281/
 000119312526458378/eldn-ex99_1.htm\nDetails and all sources: https://sec-a
 pi.dev/companies/eldn/catalysts\nData as of 2026-11-16. sec-api.dev biotec
 h catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/eldn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:af0bfcbff391fd8f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ELITE PHARMACEUTICALS INC /NV/ earnings report (ELTP)
DESCRIPTION:ELITE PHARMACEUTICALS INC /NV/ earnings report (ELTP): November
  12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): 
 "Pharmaceuticals\, Inc. Reports Financial Results for the Second Quarter o
 f Fiscal Year 2027 ended September 30\, 2026 and" https://www.sec.gov/Arch
 ives/edgar/data/1053369/000149315226051484/ex99-1.htm\nDetails and all sou
 rces: https://sec-api.dev/companies/eltp/catalysts\nData as of 2026-11-16.
  sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/eltp/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:af1e6f904acb2614@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Pelthos Therapeutics Inc. earnings report (PTHS)
DESCRIPTION:Pelthos Therapeutics Inc. earnings report (PTHS): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Pelt
 hos Therapeutics Announces Third Quarter 2026 Financial Results and Provid
 es Business Update" https://www.sec.gov/Archives/edgar/data/1919246/000191
 924626000134/pths-pressreleasex20261112.htm\nDetails and all sources: http
 s://sec-api.dev/companies/pths/catalysts\nData as of 2026-11-16. sec-api.d
 ev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/pths/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:af33ee587fed7d53@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Aktis Oncology\, Inc. earnings report (AKTS)
DESCRIPTION:Aktis Oncology\, Inc. earnings report (AKTS): November 12\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "Aktis On
 cology Reports Third-Quarter Financial Results and Highlights Clinical Tri
 al Progress" https://www.sec.gov/Archives/edgar/data/2035832/0001193125264
 57045/ck0002035832-ex99_1.htm\nDetails and all sources: https://sec-api.de
 v/companies/akts/catalysts\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/akts/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b03eecc11af89fc8@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:BioStem Technologies\, Inc. earnings report (BSEM)
DESCRIPTION:BioStem Technologies\, Inc. earnings report (BSEM): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Bi
 oStem Technologies Reports Third Quarter 2026 Financial Results\; Grows Ho
 spital Revenue for Second Consecutive Quarter as Customers Expand Use of P
 ortfolio" https://www.sec.gov/Archives/edgar/data/1658678/0001193125264583
 05/bsem-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies
 /bsem/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calen
 dar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/bsem/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b0b8ca53081b6473@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Lineage Cell Therapeutics\, Inc. earnings report (LCTX)
DESCRIPTION:Lineage Cell Therapeutics\, Inc. earnings report (LCTX): Novemb
 er 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99)
 : "LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS 
 AND PROVIDES BUSINESS UPDATE" https://www.sec.gov/Archives/edgar/data/8763
 43/000119312526458377/lctx-ex99_1.htm\nDetails and all sources: https://se
 c-api.dev/companies/lctx/catalysts\nData as of 2026-11-16. sec-api.dev bio
 tech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/lctx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b32362b735a9fa5a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Atrium Therapeutics\, Inc. earnings report (RNA)
DESCRIPTION:Atrium Therapeutics\, Inc. earnings report (RNA): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Atri
 um Therapeutics Reports Third Quarter 2026 Financial Results" https://www.
 sec.gov/Archives/edgar/data/2093101/000119312526458459/d692180dex991.htm\n
 Details and all sources: https://sec-api.dev/companies/rna/catalysts\nData
  as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.
 dev/fda-calendar).
URL:https://sec-api.dev/companies/rna/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b3d933b7e505f42a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Grace Therapeutics\, Inc. earnings report (GRCE)
DESCRIPTION:Grace Therapeutics\, Inc. earnings report (GRCE): November 12\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Grac
 e Therapeutics Announces Second Quarter 2027 Financial Results\," https://
 www.sec.gov/Archives/edgar/data/1444192/000114036126043308/ef20085030_ex99
 -1.htm\nDetails and all sources: https://sec-api.dev/companies/grce/cataly
 sts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:/
 /sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/grce/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b884f098ec045384@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:SUTRO BIOPHARMA\, INC. earnings report (STRO)
DESCRIPTION:SUTRO BIOPHARMA\, INC. earnings report (STRO): November 12\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Sutro B
 iopharma Reports Third Quarter 2026 Financial Results and Business Highlig
 hts" https://www.sec.gov/Archives/edgar/data/1382101/000119312526458641/st
 ro-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/stro
 /catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (
 https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/stro/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bb83ea3ce282825f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Scribe Therapeutics\, Inc. earnings report (SCTX)
DESCRIPTION:Scribe Therapeutics\, Inc. earnings report (SCTX): November 12\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Scr
 ibe Therapeutics Reports Third Quarter 2026 Financial Results and Recent C
 orporate Highlights" https://www.sec.gov/Archives/edgar/data/1853921/00011
 9312526458486/sctx-ex99_1.htm\nDetails and all sources: https://sec-api.de
 v/companies/sctx/catalysts\nData as of 2026-11-16. sec-api.dev biotech cat
 alyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/sctx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bb97548e5081f42a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Monopar Therapeutics earnings report (MNPR)
DESCRIPTION:Monopar Therapeutics earnings report (MNPR): November 12\, 2026
 . Status: completed.\nPress release filed with the SEC (EX-99): "Wilmette\
 , IL\, November 12\, 2026 - Monopar Therapeutics Inc. ("Monopar" or the "C
 ompany") (Nasdaq: MNPR)\, a clinical-stage biopharmaceutical company devel
 oping innovative treatments for patients with unmet medical needs\, today 
 announced third quarter 2026 financial results and provided business updat
 es." https://www.sec.gov/Archives/edgar/data/1645469/000143774926036385/ex
 _1043550.htm\nDetails and all sources: https://sec-api.dev/companies/mnpr/
 catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (h
 ttps://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mnpr/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d211576acbc57bb6@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:SELLAS Life Sciences Group\, Inc. earnings report (SLS)
DESCRIPTION:SELLAS Life Sciences Group\, Inc. earnings report (SLS): Novemb
 er 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99)
 : "SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and P
 rovides Corporate Update" https://www.sec.gov/Archives/edgar/data/1390478/
 000139047826000021/sls-202611128xkexhibit991.htm\nDetails and all sources:
  https://sec-api.dev/companies/sls/catalysts\nData as of 2026-11-16. sec-a
 pi.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/sls/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d491f45fa57a5fd0@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:PROKIDNEY CORP. earnings report (PROK)
DESCRIPTION:PROKIDNEY CORP. earnings report (PROK): November 12\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "ProKidney Repo
 rts Third Quarter 2026 Financial Results and Business Highlights" https://
 www.sec.gov/Archives/edgar/data/1850270/000119312526458470/prok-ex99_1.htm
 \nDetails and all sources: https://sec-api.dev/companies/prok/catalysts\nD
 ata as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-a
 pi.dev/fda-calendar).
URL:https://sec-api.dev/companies/prok/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:db5cba671193319e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:CorMedix Inc. earnings report (CRMD)
DESCRIPTION:CorMedix Inc. earnings report (CRMD): November 12\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "CORMEDIX THERAPE
 UTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS U
 PDATE" https://www.sec.gov/Archives/edgar/data/1410098/000141009826000063/
 crmd_q32026earningspr.htm\nDetails and all sources: https://sec-api.dev/co
 mpanies/crmd/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/crmd/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dde5a01806095f84@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:4D Molecular Therapeutics\, Inc. earnings report (FDMT)
DESCRIPTION:4D Molecular Therapeutics\, Inc. earnings report (FDMT): Novemb
 er 12\, 2026. Status: completed.\nPress release filed with the SEC (EX-99)
 : "4DMT Reports Third Quarter 2026 Financial Results\, Operational Highlig
 hts and Expected Upcoming Milestones" https://www.sec.gov/Archives/edgar/d
 ata/1650648/000119312526458394/fdmt-ex99_1.htm\nDetails and all sources: h
 ttps://sec-api.dev/companies/fdmt/catalysts\nData as of 2026-11-16. sec-ap
 i.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/fdmt/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:df23def92321271e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Century Therapeutics\, Inc. earnings report (IPSC)
DESCRIPTION:Century Therapeutics\, Inc. earnings report (IPSC): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Ce
 ntury Therapeutics Reports Third Quarter 2026 Financial Results and Busine
 ss Updates" https://www.sec.gov/Archives/edgar/data/1850119/00011046592612
 5830/tm2629581d1_ex99-1.htm\nDetails and all sources: https://sec-api.dev/
 companies/ipsc/catalysts\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/ipsc/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e386ad04ff7e58fc@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Imunon\, Inc. earnings report (IMNN)
DESCRIPTION:Imunon\, Inc. earnings report (IMNN): November 12\, 2026. Statu
 s: completed.\nPress release filed with the SEC (EX-99): "Reports Third Qu
 arter 2026 Financial Results and Provides Business Update" https://www.sec
 .gov/Archives/edgar/data/749647/000149315226051202/ex99-1.htm\nDetails and
  all sources: https://sec-api.dev/companies/imnn/catalysts\nData as of 202
 6-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-ca
 lendar).
URL:https://sec-api.dev/companies/imnn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e48019793acc4718@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ANAPTYSBIO\, INC earnings report (ANAB)
DESCRIPTION:ANAPTYSBIO\, INC earnings report (ANAB): November 12\, 2026. St
 atus: completed.\nPress release filed with the SEC (EX-99): "Anaptys Repor
 ts Fiscal First Quarter 2027 Financial Results and" https://www.sec.gov/Ar
 chives/edgar/data/1370053/000119312526458461/anab-ex99_1.htm\nDetails and 
 all sources: https://sec-api.dev/companies/anab/catalysts\nData as of 2026
 -11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-cal
 endar).
URL:https://sec-api.dev/companies/anab/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e51a454caec91a69@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:MACROGENICS INC earnings report (MGNX)
DESCRIPTION:MACROGENICS INC earnings report (MGNX): November 12\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "MacroGenics Re
 ports Third Quarter 2026 Financial Results and Highlights Recent Corporate
  Progress" https://www.sec.gov/Archives/edgar/data/1125345/000112534526000
 074/exhibit99-1earningspressre.htm\nDetails and all sources: https://sec-a
 pi.dev/companies/mgnx/catalysts\nData as of 2026-11-16. sec-api.dev biotec
 h catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mgnx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e7363ec4dc61f962@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:CV Sciences\, Inc. earnings report (CVSI)
DESCRIPTION:CV Sciences\, Inc. earnings report (CVSI): November 12\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "CV Sciences
 \, Inc. Reports Third Quarter-End 2026 Financial Results" https://www.sec.
 gov/Archives/edgar/data/1510964/000119312526458290/cvsi-ex99_1.htm\nDetail
 s and all sources: https://sec-api.dev/companies/cvsi/catalysts\nData as o
 f 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/f
 da-calendar).
URL:https://sec-api.dev/companies/cvsi/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e74b7715244f74d2@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Electra Therapeutics\, Inc. earnings report (ETRA)
DESCRIPTION:Electra Therapeutics\, Inc. earnings report (ETRA): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "El
 ectra Therapeutics Reports Third Quarter 2026 Financial Results and Recent
  Portfolio Highlights" https://www.sec.gov/Archives/edgar/data/2088082/000
 119312526458464/etra-ex99_1.htm\nDetails and all sources: https://sec-api.
 dev/companies/etra/catalysts\nData as of 2026-11-16. sec-api.dev biotech c
 atalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/etra/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e95f2facac5a4203@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:DiaMedica Therapeutics Inc. earnings report (DMAC)
DESCRIPTION:DiaMedica Therapeutics Inc. earnings report (DMAC): November 12
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Mi
 nneapolis\, Minnesota - November 12\, 2026 (Business Wire) - DiaMedica The
 rapeutics Inc. ("DiaMedica" or the "Company") (Nasdaq: DMAC)\, a clinical-
 stage biopharmaceutical company focused on developing novel treatments for
  preeclampsia (PE)\, fetal growth restriction (FGR) and acute ischemic str
 oke (AIS)\, today provided a business update and reported financial result
 s for the third quarter ended September 30\, 2026." https://www.sec.gov/Ar
 chives/edgar/data/1401040/000143774926036600/ex_1044414.htm\nDetails and a
 ll sources: https://sec-api.dev/companies/dmac/catalysts\nData as of 2026-
 11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-cale
 ndar).
URL:https://sec-api.dev/companies/dmac/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f0bce75f113fb122@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Benitec Biopharma Inc. earnings report (BNTC)
DESCRIPTION:Benitec Biopharma Inc. earnings report (BNTC): November 12\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "HAYWARD
 \, Calif.\, Nov.13\, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASD
 AQ: BNTC) ("Benitec" or the "Company")\, a clinical-stage biotechnology co
 mpany developing disease-modifying genetic medicines for life-threatening\
 , genetically defined diseases\, based on its proprietary "Silence and Rep
 lace" DNA-directed RNA interference ("ddRNAi") platform\, today announced 
 financial results for its first fiscal quarter ended September 30\, 2026\,
  and provided an update on recent clinical data presentations." https://ww
 w.sec.gov/Archives/edgar/data/1808898/000119312526459339/bntc-ex99_1.htm\n
 Details and all sources: https://sec-api.dev/companies/bntc/catalysts\nDat
 a as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api
 .dev/fda-calendar).
URL:https://sec-api.dev/companies/bntc/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fd0b2f666f3fe015@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Theriva Biologics\, Inc. earnings report (TOVX)
DESCRIPTION:Theriva Biologics\, Inc. earnings report (TOVX): November 12\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Biolo
 gics Reports Third Quarter 2026 Operational Highlights and Financial Resul
 ts" https://www.sec.gov/Archives/edgar/data/894158/000110465926125912/tm26
 29526d1_ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies
 /tovx/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calen
 dar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tovx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fd8f8716efca1d7a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:ALUMIS INC. earnings report (ALMS)
DESCRIPTION:ALUMIS INC. earnings report (ALMS): November 12\, 2026. Status:
  completed.\nPress release filed with the SEC (EX-99): "Alumis Reports Thi
 rd Quarter 2026 Financial Results and" https://www.sec.gov/Archives/edgar/
 data/1847367/000184736726000022/alms-ex99d1.htm\nDetails and all sources: 
 https://sec-api.dev/companies/alms/catalysts\nData as of 2026-11-16. sec-a
 pi.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/alms/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ff850581623a8a94@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Altimmune\, Inc. earnings report (ALT)
DESCRIPTION:Altimmune\, Inc. earnings report (ALT): November 12\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "Altimmune Anno
 unces Third Quarter 2026 Financial Results and Business Update" https://ww
 w.sec.gov/Archives/edgar/data/1326190/000132619026000067/alt-ex99d1.htm\nD
 etails and all sources: https://sec-api.dev/companies/alt/catalysts\nData 
 as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.d
 ev/fda-calendar).
URL:https://sec-api.dev/companies/alt/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:nct05093634-readout@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261116T102001Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:IMCIVREE® (setmelanotide) topline data readout (RYTM)
DESCRIPTION:IMCIVREE® (setmelanotide) topline data readout (RYTM): Novembe
 r 12\, 2026. Status: completed.\nClinicalTrials.gov: "NCT05093634 (EMANATE
 : A Study of Setmelanotide in Patients With Specific Gene Variants in the 
 MC4R Pathway): Overall Status COMPLETED\; Phase PHASE3\; Primary Completio
 n 2025-12-19 (ACTUAL)\; Lead Sponsor Rhythm Pharmaceuticals\, Inc.\; Resul
 ts First Posted 2026-11-12." https://clinicaltrials.gov/study/NCT05093634?
 tab=results\nDetails and all sources: https://sec-api.dev/pdufa/setmelanot
 ide\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:/
 /sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/setmelanotide
CATEGORIES:topline data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:nct05459571-readout@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261116T102001Z
DTSTART;VALUE=DATE:20261112
DTEND;VALUE=DATE:20261113
SUMMARY:Yescarta (axicabtagene ciloleucel) topline data readout (GILD)
DESCRIPTION:Yescarta (axicabtagene ciloleucel) topline data readout (GILD):
  November 12\, 2026. Status: completed.\nClinicalTrials.gov: "NCT05459571 
 (Study of Axicabtagene Ciloleucel Given With Steroids In Participants With
  Relapsed Or Refractory Large B-Cell Lymphoma): Overall Status COMPLETED\;
  Phase PHASE2\; Primary Completion 2025-11-24 (ACTUAL)\; Lead Sponsor Kite
 \, A Gilead Company\; Results First Posted 2026-11-12." https://clinicaltr
 ials.gov/study/NCT05459571?tab=results\nDetails and all sources: https://s
 ec-api.dev/pdufa/axicabtagene-ciloleucel\nData as of 2026-11-16. sec-api.d
 ev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/axicabtagene-ciloleucel
CATEGORIES:topline data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0f01219a1168255e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:TuHURA Biosciences\, Inc./NV earnings report (HURA)
DESCRIPTION:TuHURA Biosciences\, Inc./NV earnings report (HURA): November 1
 3\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "T
 uHURA Biosciences Reports Third Quarter 2026 Financial Results and Provide
 s a Corporate Update" https://www.sec.gov/Archives/edgar/data/1498382/0001
 19312526459311/hura-ex99_1.htm\nDetails and all sources: https://sec-api.d
 ev/companies/hura/catalysts\nData as of 2026-11-16. sec-api.dev biotech ca
 talyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/hura/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:271d855c829daa8e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Cingulate Inc. earnings report (CING)
DESCRIPTION:Cingulate Inc. earnings report (CING): November 13\, 2026. Stat
 us: completed.\nPress release filed with the SEC (EX-99): "Inc. Reports Th
 ird Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1
 301 NDA Resubmission" https://www.sec.gov/Archives/edgar/data/1862150/0001
 49315226051841/ex99-1.htm\nDetails and all sources: https://sec-api.dev/co
 mpanies/cing/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cing/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2b10ccdd88fc5395@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Indaptus Therapeutics\, Inc. earnings report (INDP)
DESCRIPTION:Indaptus Therapeutics\, Inc. earnings report (INDP): November 1
 3\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "T
 herapeutics Reports Third Quarter 2026 Financial Results and Provides Corp
 orate Update" https://www.sec.gov/Archives/edgar/data/1857044/000149315226
 051749/ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/
 indp/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calend
 ar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/indp/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:329553bf362a9044@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:IMMUNIC\, INC. earnings report (IMUX)
DESCRIPTION:IMMUNIC\, INC. earnings report (IMUX): November 13\, 2026. Stat
 us: completed.\nPress release filed with the SEC (EX-99): "Inc. Reports Th
 ird Quarter 2026 Financial Results and Provides Corporate Update" https://
 www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm\nDet
 ails and all sources: https://sec-api.dev/companies/imux/catalysts\nData a
 s of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.de
 v/fda-calendar).
URL:https://sec-api.dev/companies/imux/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3bbf1ef4e014bec1@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:TRex Bio\, Inc. earnings report (TRXB)
DESCRIPTION:TRex Bio\, Inc. earnings report (TRXB): November 13\, 2026. Sta
 tus: completed.\nPress release filed with the SEC (EX-99): "TRexBio Report
 s Third Quarter 2026 Financial Results and Recent Business Highlights" htt
 ps://www.sec.gov/Archives/edgar/data/2139097/000119312526460588/ck00021390
 97-ex99_1.htm\nDetails and all sources: https://sec-api.dev/companies/trxb
 /catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (
 https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/trxb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:43036c481bd4b416@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Tempest Therapeutics\, Inc. earnings report (TPST)
DESCRIPTION:Tempest Therapeutics\, Inc. earnings report (TPST): November 13
 \, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "T-
 cell ("CAR-T") product candidates to treat cancer and autoimmune disease\,
  today reported financial results for the quarter ended September 30\, 202
 6\, and provided a business update." https://www.sec.gov/Archives/edgar/da
 ta/1544227/000121390026119916/ea031215701ex99-1.htm\nDetails and all sourc
 es: https://sec-api.dev/companies/tpst/catalysts\nData as of 2026-11-16. s
 ec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/tpst/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:443c0e19166f8e2a@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Milestone Pharmaceuticals Inc. earnings report (MIST)
DESCRIPTION:Milestone Pharmaceuticals Inc. earnings report (MIST): November
  13\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): 
 "Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announce
 s Cost-Efficiency Measures Designed to Extend Cash Runway Through" https:/
 /www.sec.gov/Archives/edgar/data/1408443/000110465926126519/tm2629645d1_ex
 99-1.htm\nDetails and all sources: https://sec-api.dev/companies/mist/cata
 lysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https
 ://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mist/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4bb950df5624266e@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:BeyondSpring Inc. earnings report (BYSI)
DESCRIPTION:BeyondSpring Inc. earnings report (BYSI): November 13\, 2026. S
 tatus: completed.\nPress release filed with the SEC (EX-99): "BeyondSpring
  Reports Third-Quarter 2026 Financial Results and Provides Corporate Updat
 e" https://www.sec.gov/Archives/edgar/data/1677940/000117184326007431/exh_
 991.htm\nDetails and all sources: https://sec-api.dev/companies/bysi/catal
 ysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https:
 //sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/bysi/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:58cae7251f486e2d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Tvardi Therapeutics\, Inc. earnings report (TVRD)
DESCRIPTION:Tvardi Therapeutics\, Inc. earnings report (TVRD): November 13\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Tva
 rdi Therapeutics Announces Third Quarter 2026 Results and" https://www.sec
 .gov/Archives/edgar/data/1346830/000110465926126507/tvrd-ex99d1.htm\nDetai
 ls and all sources: https://sec-api.dev/companies/tvrd/catalysts\nData as 
 of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/
 fda-calendar).
URL:https://sec-api.dev/companies/tvrd/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:59d41214246f21a3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Aardvark Therapeutics\, Inc. earnings report (AARD)
DESCRIPTION:Aardvark Therapeutics\, Inc. earnings report (AARD): November 1
 3\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "A
 ardvark Therapeutics Reports Third Quarter 2026 Financial Results and Prov
 ides Business Updates" https://www.sec.gov/Archives/edgar/data/1774857/000
 119312526459373/ck0001774857-ex99_1.htm\nDetails and all sources: https://
 sec-api.dev/companies/aard/catalysts\nData as of 2026-11-16. sec-api.dev b
 iotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/aard/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5cac12d14b89e273@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Vistagen Therapeutics\, Inc. earnings report (VTGN)
DESCRIPTION:Vistagen Therapeutics\, Inc. earnings report (VTGN): November 1
 3\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "V
 istagen Reports Fiscal Year 2027 Second Quarter Financial Results and Prov
 ides Corporate Update" https://www.sec.gov/Archives/edgar/data/1411685/000
 162828026073824/vtgn-20261112xex991.htm\nDetails and all sources: https://
 sec-api.dev/companies/vtgn/catalysts\nData as of 2026-11-16. sec-api.dev b
 iotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/vtgn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5e36adebb75032d3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Jade Biosciences\, Inc. earnings report (JBIO)
DESCRIPTION:Jade Biosciences\, Inc. earnings report (JBIO): November 13\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Jade B
 iosciences Reports Third Quarter 2026 Financial Results and Provides Corpo
 rate Update" https://www.sec.gov/Archives/edgar/data/1798749/0001193125264
 59287/d157312dex991.htm\nDetails and all sources: https://sec-api.dev/comp
 anies/jbio/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst 
 calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/jbio/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:79ecd2fb41f996b3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Inhibrx Biosciences\, Inc. earnings report (INBX)
DESCRIPTION:Inhibrx Biosciences\, Inc. earnings report (INBX): November 13\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Inh
 ibrx Reports Third Quarter 2026 Financial Results" https://www.sec.gov/Arc
 hives/edgar/data/2007919/000200791926000057/exhibit99109302026.htm\nDetail
 s and all sources: https://sec-api.dev/companies/inbx/catalysts\nData as o
 f 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/f
 da-calendar).
URL:https://sec-api.dev/companies/inbx/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7d9bb3d913db144f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Calidi Biotherapeutics\, Inc. earnings report (CLDI)
DESCRIPTION:Calidi Biotherapeutics\, Inc. earnings report (CLDI): November 
 13\, 2026. Status: completed.\nPress release filed with the SEC (EX-99): "
 Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Re
 cent Business Highlights" https://www.sec.gov/Archives/edgar/data/1855485/
 000119312526460816/cldi-ex99_1.htm\nDetails and all sources: https://sec-a
 pi.dev/companies/cldi/catalysts\nData as of 2026-11-16. sec-api.dev biotec
 h catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/cldi/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8d6d4ac9a05b469d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Biofrontera Inc. earnings report (BFRI)
DESCRIPTION:Biofrontera Inc. earnings report (BFRI): November 13\, 2026. St
 atus: completed.\nPress release filed with the SEC (EX-99): "Inc. Reports 
 Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year R
 evenue Growth" https://www.sec.gov/Archives/edgar/data/1858685/00014931522
 6051546/ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies
 /bfri/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calen
 dar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/bfri/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:919dfe8e1f3ac621@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:INTEGRATED BIOPHARMA INC earnings report (INBP)
DESCRIPTION:INTEGRATED BIOPHARMA INC earnings report (INBP): November 13\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "HILLS
 IDE\, NEW JERSEY (November 13\, 2026) - Integrated BioPharma\, Inc. (OTCQX
 : INBP) (the "Company" or "INBP") reports its financial results for the qu
 arter ended September 30\, 2026." https://www.sec.gov/Archives/edgar/data/
 1016504/000143774926036730/ex_1043877.htm\nDetails and all sources: https:
 //sec-api.dev/companies/inbp/catalysts\nData as of 2026-11-16. sec-api.dev
  biotech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/inbp/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:980d38305713628c@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:PDS Biotechnology Corp earnings report (PDSB)
DESCRIPTION:PDS Biotechnology Corp earnings report (PDSB): November 13\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "PDS Bio
 tech Reports Third Quarter 2026 Financial Results" https://www.sec.gov/Arc
 hives/edgar/data/1472091/000114036126043542/ef20085528_ex99-1.htm\nDetails
  and all sources: https://sec-api.dev/companies/pdsb/catalysts\nData as of
  2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fd
 a-calendar).
URL:https://sec-api.dev/companies/pdsb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9d920e4e770d055d@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:MetaVia Inc. earnings report (MTVA)
DESCRIPTION:MetaVia Inc. earnings report (MTVA): November 13\, 2026. Status
 : completed.\nPress release filed with the SEC (EX-99): "MetaVia Reports T
 hird Quarter 2026 Financial Results and Provides Corporate Update" https:/
 /www.sec.gov/Archives/edgar/data/1638287/000110465926126540/mtva-ex99d1.ht
 m\nDetails and all sources: https://sec-api.dev/companies/mtva/catalysts\n
 Data as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-
 api.dev/fda-calendar).
URL:https://sec-api.dev/companies/mtva/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a3c9d2bc2aba3411@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Fortress Biotech\, Inc. earnings report (FBIO)
DESCRIPTION:Fortress Biotech\, Inc. earnings report (FBIO): November 13\, 2
 026. Status: completed.\nPress release filed with the SEC (EX-99): "Fortre
 ss Biotech Reports Third Quarter 2026 Financial Results and Recent Corpora
 te Highlights" https://www.sec.gov/Archives/edgar/data/1429260/00011046592
 6126525/fbio-ex99d1.htm\nDetails and all sources: https://sec-api.dev/comp
 anies/fbio/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst 
 calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/fbio/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b8753afd1decd9cc@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Xenetic Biosciences\, Inc. earnings report (XBIO)
DESCRIPTION:Xenetic Biosciences\, Inc. earnings report (XBIO): November 13\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Rep
 orts Third Quarter 2026 Financial Results and Highlights Strategic Busines
 s Updates" https://www.sec.gov/Archives/edgar/data/1534525/000168316826008
 650/xenetic_ex9901.htm\nDetails and all sources: https://sec-api.dev/compa
 nies/xbio/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst c
 alendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/xbio/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bf099be7ec956147@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:IRulya Therapeutics Inc. earnings report (IRLA)
DESCRIPTION:IRulya Therapeutics Inc. earnings report (IRLA): November 13\, 
 2026. Status: completed.\nPress release filed with the SEC (EX-99): "IRuly
 a Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Fi
 nancial Results" https://www.sec.gov/Archives/edgar/data/1662774/000119312
 526460775/d190919dex991.htm\nDetails and all sources: https://sec-api.dev/
 companies/irla/catalysts\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/irla/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c1e10e7c73b1f3a4@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Evofem Biosciences\, Inc. earnings report (EVFM)
DESCRIPTION:Evofem Biosciences\, Inc. earnings report (EVFM): November 13\,
  2026. Status: completed.\nPress release filed with the SEC (EX-99): "Repo
 rts Third Quarter 2026 Financial Results and Provides Business Update" htt
 ps://www.sec.gov/Archives/edgar/data/1618835/000149315226051806/ex99-1.htm
 \nDetails and all sources: https://sec-api.dev/companies/evfm/catalysts\nD
 ata as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-a
 pi.dev/fda-calendar).
URL:https://sec-api.dev/companies/evfm/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cb3546472c629e58@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Xenetic Biosciences\, Inc. trial start (XBIO)
DESCRIPTION:Xenetic Biosciences\, Inc. trial start (XBIO): November 13\, 20
 26. Status: completed.\nPress release filed with the SEC (EX-99): "Initiat
 ed Clinical Evaluation of DNase I in Combination with CAR T-Cell Therapy: 
 Announced the first patient dosed in an investigator-initiated\, Phase I (
 NCT07361224) clinical study evaluating systemic recombinant human DNase I 
 in combination with anti-CD19 CAR T-cell therapy in patients with large B-
 cell lymphoma (LBCL)." https://www.sec.gov/Archives/edgar/data/1534525/000
 168316826008650/xenetic_ex9901.htm\nDetails and all sources: https://sec-a
 pi.dev/companies/xbio/catalysts\nData as of 2026-11-16. sec-api.dev biotec
 h catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/xbio/catalysts
CATEGORIES:trial start
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d20544f02edb7950@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:TherapeuticsMD\, Inc. earnings report (TXMD)
DESCRIPTION:TherapeuticsMD\, Inc. earnings report (TXMD): November 13\, 202
 6. Status: completed.\nPress release filed with the SEC (EX-99): "PRESS RE
 LEASE FROM THERAPEUTICSMD\, INC.\, DATED NOVEMBER 13\, 2026\, ENTITLED "TH
 ERAPEUTICSMD ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS."" https://ww
 w.sec.gov/Archives/edgar/data/25743/000121390026119681/ea031220401ex99-1.h
 tm\nDetails and all sources: https://sec-api.dev/companies/txmd/catalysts\
 nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec
 -api.dev/fda-calendar).
URL:https://sec-api.dev/companies/txmd/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ed37a8e55fdfa900@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Enveric Biosciences\, Inc. earnings report (ENVB)
DESCRIPTION:Enveric Biosciences\, Inc. earnings report (ENVB): November 13\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Bio
 sciences Reports Financial Results for Third Quarter 2026 and Provides Cor
 porate Update" https://www.sec.gov/Archives/edgar/data/890821/000149315226
 051708/ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/
 envb/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calend
 ar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/envb/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f33bf68a110508b3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Annovis Bio\, Inc. earnings report (ANVS)
DESCRIPTION:Annovis Bio\, Inc. earnings report (ANVS): November 13\, 2026. 
 Status: completed.\nPress release filed with the SEC (EX-99): "Annovis Pro
 vides Corporate Updates and Reports Third Quarter 2026 Financial Results" 
 https://www.sec.gov/Archives/edgar/data/1477845/000110465926127094/tm26297
 28d1_ex99-1.htm\nDetails and all sources: https://sec-api.dev/companies/an
 vs/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar
  (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/anvs/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:nct03850782-readout@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261116T102001Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:Bimatoprost (sr) topline data readout (ABBV)
DESCRIPTION:Bimatoprost (sr) topline data readout (ABBV): November 13\, 202
 6. Status: completed.\nClinicalTrials.gov: "NCT03850782 (Evaluation of the
  Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glau
 coma or Ocular Hypertension): Overall Status COMPLETED\; Phase PHASE3\; Pr
 imary Completion 2025-08-08 (ACTUAL)\; Lead Sponsor AbbVie\; Results First
  Posted 2026-11-13." https://clinicaltrials.gov/study/NCT03850782?tab=resu
 lts\nDetails and all sources: https://sec-api.dev/pdufa/bimatoprost-sr\nDa
 ta as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://sec-ap
 i.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/bimatoprost-sr
CATEGORIES:topline data readout
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:30ce12258a111dba@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261104T000000Z
DTSTART;VALUE=DATE:20261114
DTEND;VALUE=DATE:20261115
SUMMARY:MYQORZO® (aficamten) PDUFA date (CYTK)
DESCRIPTION:MYQORZO® (aficamten) PDUFA date (CYTK): November 14\, 2026. St
 atus: scheduled.\nPress release filed with the SEC (EX-99): "MYQORZO Appro
 ved by the European Commission for Adults with Symptomatic Obstructive HCM
 \; Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Da
 te of November 14\, 2026" https://www.sec.gov/Archives/edgar/data/1061983/
 000119312526206360/cytk-ex99_1.htm\nDetails and all sources: https://sec-a
 pi.dev/pdufa/aficamten\nData as of 2026-11-16. sec-api.dev biotech catalys
 t calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/aficamten
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:471992d7ca385656@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20260813T000000Z
DTSTART;VALUE=DATE:20261114
DTEND;VALUE=DATE:20261115
SUMMARY:IGALMI® (dexmedetomidine) PDUFA date (BTAIQ)
DESCRIPTION:IGALMI® (dexmedetomidine) PDUFA date (BTAIQ): November 14\, 20
 26. Status: scheduled.\nPress release filed with the SEC (EX-99): "FDA acc
 epted sNDA for IGALMI® use in at-home (outpatient) setting\; set Nov. 14\
 , 2026\, as PDUFA date" https://www.sec.gov/Archives/edgar/data/1720893/00
 0110465926061773/tm2614679d1_ex99-1.htm\nDetails and all sources: https://
 sec-api.dev/pdufa/dexmedetomidine\nData as of 2026-11-16. sec-api.dev biot
 ech catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/dexmedetomidine
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f927662242e97b63@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261104T000000Z
DTSTART;VALUE=DATE:20261114
DTEND;VALUE=DATE:20261115
SUMMARY:Ivonescimab PDUFA date (SMMT)
DESCRIPTION:Ivonescimab PDUFA date (SMMT): November 14\, 2026. Status: comp
 leted (crl).\nSEC Form 10-K: "In January 2026\, the FDA accepted for filin
 g our BLA seeking approval of ivonescimab in combination with chemotherapy
  in patients with EGFR-mutated locally advanced or metastatic non-squamous
  NSCLC post-TKI therapy and provided a PDUFA target action date of Novembe
 r 14\, 2026." https://www.sec.gov/Archives/edgar/data/1599298/000159929826
 000015/smmt-20251231.htm\nDetails and all sources: https://sec-api.dev/pdu
 fa/ivonescimab\nData as of 2026-11-16. sec-api.dev biotech catalyst calend
 ar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/ivonescimab
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e89539e821f1e1f3@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261116T000000Z
DTSTART;VALUE=DATE:20261115
DTEND;VALUE=DATE:20261116
SUMMARY:Ivonescimab complete response letter (CRL) (SMMT)
DESCRIPTION:Ivonescimab complete response letter (CRL) (SMMT): November 15\
 , 2026. Status: completed (crl).\nSEC Form 8-K: "On November 15\, 2026\, S
 ummit Therapeutics Inc. issued a press release announcing that the U.S. Fo
 od and Drug Administration (the "FDA") has issued a Complete Response Lett
 er ("CRL") regarding the Biologics License Application ("BLA") for ivonesc
 imab in combination with platinum-containing chemotherapy for the treatmen
 t of patients with locally advanced or metastatic non-small cell lung canc
 er\, who have received prior epidermal growth factor receptor tyrosine kin
 ase inhibitor therapy." https://www.sec.gov/Archives/edgar/data/1599298/00
 0159929826000092/smmt-20261115.htm\nDetails and all sources: https://sec-a
 pi.dev/pdufa/ivonescimab\nData as of 2026-11-16. sec-api.dev biotech catal
 yst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/ivonescimab
CATEGORIES:complete response letter (CRL)
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7487cefa9e20ed47@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261116T000000Z
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20261117
SUMMARY:Silexion Therapeutics Corp earnings report (SLXN)
DESCRIPTION:Silexion Therapeutics Corp earnings report (SLXN): November 16\
 , 2026. Status: completed.\nPress release filed with the SEC (EX-99): "Rep
 orts Third Quarter 2026 Financial Results and" https://www.sec.gov/Archive
 s/edgar/data/2022416/000117891326005216/exhibit_99-1.htm\nDetails and all 
 sources: https://sec-api.dev/companies/slxn/catalysts\nData as of 2026-11-
 16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calenda
 r).
URL:https://sec-api.dev/companies/slxn/catalysts
CATEGORIES:earnings report
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:121b0a25fbfb0651@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261109T000000Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Savara Inc PDUFA date (SVRA)
DESCRIPTION:Savara Inc PDUFA date (SVRA): November 22\, 2026. Status: sched
 uled.\nSEC Form 10-Q: "The FDA determined that the Company's responses to 
 recent information requests by the Agency during its review constituted a 
 major amendment to the BLA\, resulting in a three-month extension of the P
 rescription Drug User Fee Act ("PDUFA") target action date to November 22\
 , 2026." https://www.sec.gov/Archives/edgar/data/1160308/00011931252645353
 5/svra-20260930.htm\nDetails and all sources: https://sec-api.dev/companie
 s/svra/catalysts\nData as of 2026-11-16. sec-api.dev biotech catalyst cale
 ndar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/companies/svra/catalysts
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e9eaca412ace39d5@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261110T000000Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Deramiocel PDUFA date (CAPR)
DESCRIPTION:Deramiocel PDUFA date (CAPR): November 22\, 2026. Status: sched
 uled.\nPress release filed with the SEC (EX-99): "Deramiocel Biologics Lic
 ense Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA rev
 iew\; PDUFA target action date of November 22\, 2026" https://www.sec.gov/
 Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm\nDetails an
 d all sources: https://sec-api.dev/pdufa/deramiocel\nData as of 2026-11-16
 . sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar)
 .
URL:https://sec-api.dev/pdufa/deramiocel
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0d426747301c6c8b@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20260730T000000Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Venglustat PDUFA date (SNY)
DESCRIPTION:Venglustat PDUFA date (SNY): November 25\, 2026. Status: schedu
 led.\nPress release filed with the SEC (EX-99): "The target action date fo
 r the FDA decision is November 25\, 2026." https://www.sec.gov/Archives/ed
 gar/data/1121404/000112140426000008/pressreleaseq22026english.htm\nDetails
  and all sources: https://sec-api.dev/pdufa/venglustat\nData as of 2026-11
 -16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calend
 ar).
URL:https://sec-api.dev/pdufa/venglustat
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d3d04a31fcbfe498@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261029T000000Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:Ribitol PDUFA date (BBIO)
DESCRIPTION:Ribitol PDUFA date (BBIO): November 27\, 2026. Status: schedule
 d.\nPress release filed with the SEC (EX-99): "- BBP-418 for LGMD2I/R9 has
  a November 27\, 2026 PDUFA date\, with Priority Review." https://www.sec.
 gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm
 \nDetails and all sources: https://sec-api.dev/pdufa/ribitol\nData as of 2
 026-11-16. sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-
 calendar).
URL:https://sec-api.dev/pdufa/ribitol
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:709a1320328e1f7f@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261105T000000Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bezuclastinib PDUFA date (COGT)
DESCRIPTION:Bezuclastinib PDUFA date (COGT): November 30\, 2026. Status: sc
 heduled.\nPress release filed with the SEC (EX-99): "Preparing for anticip
 ated bezuclastinib launch in GIST\; PDUFA action date November 30\, 2026" 
 https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex
 99_1.htm\nDetails and all sources: https://sec-api.dev/pdufa/bezuclastinib
 \nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (https://se
 c-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/bezuclastinib
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d393ec0ba051d747@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261113T000000Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Povetacicept PDUFA date (VRTX)
DESCRIPTION:Povetacicept PDUFA date (VRTX): November 30\, 2026. Status: sch
 eduled.\nPress release filed with the SEC (EX-99): "•The BLA submission 
 for accelerated approval of povetacicept in IgAN is under priority review 
 by the U.S. FDA\, with an assigned PDUFA target action date of November 30
 \, 2026." https://www.sec.gov/Archives/edgar/data/875320/00008753202600028
 7/ex-991_q32026.htm\nDetails and all sources: https://sec-api.dev/pdufa/po
 vetacicept\nData as of 2026-11-16. sec-api.dev biotech catalyst calendar (
 https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/povetacicept
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6c777be46583c4aa@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261029T000000Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Zanzalintinib PDUFA date (EXEL)
DESCRIPTION:Zanzalintinib PDUFA date (EXEL): December 3\, 2026. Status: sch
 eduled.\nPress release filed with the SEC (EX-99): ""Our first New Drug Ap
 plication for zanzalintinib\, for its initial potential indication in prev
 iously treated metastatic colorectal cancer\, was accepted by U.S. regulat
 ory authorities and is under active review\, with a target action date of 
 December 3\, 2026." https://www.sec.gov/Archives/edgar/data/939767/0000939
 76726000058/exel20260331exhibit991.htm\nDetails and all sources: https://s
 ec-api.dev/pdufa/zanzalintinib\nData as of 2026-11-16. sec-api.dev biotech
  catalyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/zanzalintinib
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c7a3acc7af5ba3be@sec-api.dev
DTSTAMP:20261116T112050Z
LAST-MODIFIED:20261112T000000Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:Imsidolimab PDUFA date (VNDA)
DESCRIPTION:Imsidolimab PDUFA date (VNDA): December 12\, 2026. Status: sche
 duled.\nPress release filed with the SEC (EX-99): "•QuimilzaTM (imsidoli
 mab) BLA for GPP under review by the FDA\; PDUFA target action date of Dec
 ember 12\, 2026" https://www.sec.gov/Archives/edgar/data/1347178/000162828
 026053308/vnda8-k852026exhibit991.htm\nDetails and all sources: https://se
 c-api.dev/pdufa/imsidolimab\nData as of 2026-11-16. sec-api.dev biotech ca
 talyst calendar (https://sec-api.dev/fda-calendar).
URL:https://sec-api.dev/pdufa/imsidolimab
CATEGORIES:PDUFA date
STATUS:CONFIRMED
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
